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CCR Chemokine receptor, CC
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DH Dermatitis herpetiformis
EMA Endomysium antibodies
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PBMC Peripheral blood mononuclear cell
PP Peyer's patches
RT-PCR Reverse transcriptase-polymerase chain reaction
SCT Stem cell transplantation
T1D Type 1 diabetes
TCR T-cell receptor
Th T-helper lymphocyte
TGF Transforming growth factor
TNF Tumour necrosis factor
tTG Tissue transglutaminase
tTGA Tissue transglutaminase antibodies
VCAM-1 Vascular cell adhesion molecule-1
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ABSTRACT
Immunologically mediated enteropathies consist of a group of different diseases that are
characterised by varying degree of villous destruction in the small intestine. Examples of
these are coeliac disease (CD), graft-versus-host disease (GvHD), and food allergy
enteropathy. In addition, immunologic changes have been observed in the small intestine of
patients with type 1 diabetes (T1D). Characteristics of these disorders are excessive T-cell
activation and production of proinflammatory cytokines. However, the knowledge of
intestinal expression of cytokines is mainly based on studies on overt CD. Knowledge of the
intestinal expression of cytokines in T1D and GvHD was, prior to this study, based only on
experimental studies. Furthermore, few studies have investigated the role of cytokines in the
early and mild forms of these intestinal inflammations.
The aim of this series of studies was to characterise the cytokine profiles and
immunologic markers in mild inflammatory disorders of the small intestine, in order to
investigate the immune activation and the role of cytokines in these diseases.
We evaluated the expression of cytokines and other immunologic markers by
immunohistochemistry, in situ hybridisation, and RT-PCR in small intestine biopsy
specimens of children 6 weeks (n=15) and 3 months (n=11) after stem cell transplantation
(SCT), and of patients with potential CD (n=10), T1D (n=31) or food allergy (n=14). We
compared the results with those of normal controls (n=18) and patients with coeliac disease
(n=13). We also investigated apoptosis of epithelial cells by in situ DNA 3'-end labelling in
biopsies of patients undergoing SCT.
We found increased densities of intraepithelial lymphocytes and IFN-γ and TNF-α
positive cells in specimens of patients with potential CD. The densities of IL-2, IFN-γ, and
TNF-α positive cells were increased in CD patients, regardless of whether they had T1D or
not. In addition, patients with T1D demonstrated increased densities of intestinal IL-4 and IL-
1α positive cells, regardless of duodenal morphology, duration of T1D or HLA-genotype. We
found a markedly increased proliferation of crypt epithelial cells in specimens of patients
undergoing SCT, who also demonstrated an increased rate of epithelial cells undergoing
apoptosis both in the crypts and in the villous surface. Additionally, SCT patients had fewer
T-cells in the lamina propria than controls, and the numbers of IFN-γ and TNF-α positive
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cells were, surprisingly, as low as in the controls. Patients with untreated food allergy, on the
other hand, showed increased number of IFN-γ positive cells.
In conclusion, we could detect inflammatory markers in the intestines of potential CD
patients long before alterations in the villous structure occurred. The increased intestinal
expression of IFN-γ and TNF-α positive cells in these patients indicates a skewing towards a
Th1-type response already at this stage. The immunologic activation, with an unexpected
Th2-dominance, in the small intestine of all patients with T1D supports the hypothesis that a
link exists between the gut immune system and type 1 diabetes. Our results on increased cell
turnover rate in SCT patients without symptomatic clinical or histological GvHD, may
represent an early stage of intestinal GvHD in humans similar to animal models. The
proposed cytokine expression in murine GvHD was not observed in our patients undergoing
SCT, which may reflect the immunosuppressive medication in SCT patients. Finally,
increased expression of IFN-γ in patients with untreated food allergy also implies a Th1-type
immune reaction in food allergy enteropathy.
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REVIEW OF THE LITERATURE
1. THE IMMUNE SYSTEM
The human body is continually exposed to infectious agents. Whether these manage to
penetrate and cause disease is dependent both on the pathogenicity of the organism and on
the body's immune system. The immune system is a complex organisation of lymphoid
organs, cells, humoral factors, and cytokines, all with specific roles in defending against
infections. There are two different types of immune responses: innate and adaptive. The
innate response is immediate and includes physical and chemical barriers, as well as
neutrophils, monocytes, macrophages, natural killer cells, complement, cytokines, and acute
phase proteins. The innate response remains the same, whereas the adaptive response
mediated by antigen-specific T- and B-lymphocytes has memory and enhances on repeated
exposure to the same microbe. In contrast to innate response, the adaptive response takes
several days or weeks to develop. Adaptive immune responses are generated in secondary
lymphoid tissues, i.e. lymph nodes, spleen and mucosa-associated lymphoid tissue.
The most important feature of the immune system is its ability to distinguish between
self and nonself. The essential function of the immune system is best demonstrated when it
does not function appropriately; hypoactivity results in severe infections and hyperactivity in
autoimmune diseases and allergy (reviewed by Delves and Roitt 2000a).
2. GUT IMMUNE SYSTEM
2.1 Structure and function
In the gut there is a delicate balance between the need to recognise pathogens and to prevent
unwanted immune responses to food antigens or the normal intestinal flora, yet allowing
adequate nutrient uptake at the same time. Considering the large area of the gastrointestinal
tract, comprising almost a 400 m2 surface in man, it is not surprising that it has developed
both immunologic and non-immunologic ways of protection. The mucosal barrier consists of
intestinal epithelial cells connected by tight junctions and of non-immunologic defence
mechanisms such as low pH, peristalsis, and mucus coat, all together protecting the intestine
from invading antigens (reviewed by Sanderson and Walker 1999).
The intestinal lymphoid tissue is the largest compartment of the immune system in the
body and referred to as the gut-associated lymphoid tissue (GALT). It consists of mesenteric
lymph nodes, Peyer's patches, isolated lymph follicles, and large numbers of lymphocytes
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scattered throughout the lamina propria and epithelium of the intestine (Mowat and Viney
1997, MacDonald 2003). Peyer's patches (PP) are organised lymphoid aggregates within the
mucosa and submucosa of the small intestine. They act as the primary inductive sites where
the interaction between luminal antigens and circulating lymphocytes occurs. The PP are
separated from the intestinal lumen by a single layer of epithelial cells, which contains
specialised epithelial cells called the microfold cells (M cells). The M cells are specialised in
antigen uptake from the intestinal lumen and transport them across the mucosal surface to the
subepithelial dome area (Neutra et al. 1996). The antigens can be taken up by several antigen-
presenting cells (APC), in which they are processed for presentation to T-cells in the PP
(Figure 1). The T-cells are activated upon antigen presentation and differentiate and mature in
the germinal centres of the follicles. They then migrate via efferent lymphatics to the
mesenteric lymph nodes before reaching the thoracic duct, and eventually the systemic
circulation. From the blood circulation these activated T-cells migrate with the help of
adhesion molecules back to the main effector sites of the intestinal immune responses; the
lamina propria and intraepithelial compartment. Here they act as effector cells, secreting
cytokines and mediating specific adaptive immune defence (Mowat and Viney 1997,
MacDonald 2003).
2.2 Cells in the gut-associated lymphoid tissue
Lamina propria is the region between the surface epithelium and the muscularis mucosa. The
majority of the cells belonging to the gut-associated lymphoid tissue are T-lymphocytes, B-
lymphocytes, and macrophages, in addition to dendritic cells, neutrophils, and low numbers
of other granulocytes and mast cells. The lamina propria is also populated by smooth muscle
cells and fibroblasts.
T-lymphocytes
T-lymphocytes are derived from pluripotent stem cells that migrate from the bone marrow to
the thymus where they mature into T-cells. In the thymus the T-cells go through a process of
positive and negative selection, that abolishes autoreactive T-cells (central tolerance)
(reviewed in Delves and Roitt 2000a, Alam and Gorska 2003). Fewer than 5% of the
developing T-cells survive this process, and T-cells with only a weak affinity for self major
histocompatibility complex (MHC) molecules leave the thymus as single positive CD4+
(helper) or CD8+ (cytotoxic) T-cells. Approximately two thirds of peripheral blood T-cells
are CD4+ and one third are CD8+.
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Figure 1. Antigen and T-cell traffic in the gut-associated lymphoid tissue (GALT). Antigen (Ag)
is taken up either via M cells or epithelial cells. Antigen processing and presentation to T-cells in the
Peyer's patch (PP) leads to the activation of T-cells, and subsequently of B-cells. The activated cells
migrate via efferent lymphatics to mesenteric lymph nodes (LN) and, after passing into the thoracic
duct, gain access to the systemic circulation. They then home back to the lamina propria and to other
mucosal and nonmucosal sites. The return of T-cells back to the gut is mediated by the interaction
between α4β7-integrin on the surface of T-cells and mucosal addressin cell adhesion molecules
(MAdCAM-1) on intestinal endothelial cells. Some soluble antigens taken up by epithelial cells also
passes through the GALT directly into the portal circulation and bloodstream. The villous epithelium
contains lymphocytes (IEL), most of which are activated CD8+ T-cells, unique for the gut. (Modified
from MacDonald and Monteleone 2001, Mowat 2003).
T-cells carry unique receptors on their cell surfaces, known as the T-cell receptors
(TCR). This receptor recognises short peptides of antigens presented in association with
MHC molecules, referred to as human leukocyte antigen (HLA) in humans, on antigen-
presenting cells. MHC class I molecules are expressed on all somatic cells in the body and
present peptides that are derived from endogenous proteins. These complexes are recognised
by CD8+ cytotoxic T-cells. MHC class II molecules on antigen-presenting cells present
exogenous peptides to CD4+ helper T-cells (Doyle and Strominger 1987). The class II
proteins are expressed on professional APCs, i.e. B-cells, neutrophils, M-cells, macrophages,
monocytes, eosinophils and basophils (Lanzavecchia 1996), but the expression can also be
induced by interferon-γ (IFN-γ) on many other cell types, including epithelial and endothelial
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cells (Skoskiewicz et al. 1985).
In humans, TCR heterodimer consists of either αβ- or γδ-chains (Brenner et al. 1986).
90-95% of circulating T-cells express the αβ form of the antigen receptor, whereas 5-10%
express TCR composed of γ and δ chains. T-cell receptors are associated on the surface of T-
cells with the CD3 complex (a marker of all T-cells) that transmit activation signals into the
cell when the T-cell receptor binds antigen. Signalling by TCR alone in the absence of
costimulatory signals, does not lead to activation of the T-cell, but to anergy or apoptosis.
The requested additional signals come from various costimulatory molecules, e.g.
costimulatory signals from the CD28-B7 interaction or CD40-CD40 ligand and LFA-
1/ICAM-1 receptor-ligand interaction, and soluble mediators such as cytokines (Noble 2000).
T-cell populations in normal human small intestine
The intestinal lamina propria and epithelium form the largest single T-cell site in the human
body. Almost all of the normal intestinal lamina propria T-cells are αβTCR positive, only 1%
being positive for γδTCR. The proportion of CD4+ and CD8+ T-cells is similar to that in the
peripheral blood. Lamina propria CD4+ T-cells express markers like CD45R0 and α4β7-
integrin, and low levels of CD25 (IL-2 receptor) and HLA-DR, indicating that they have
recently been activated by antigen (reviewed in James and Kiyono 1999). CD4+ T-cells are
considered to be the key players of the local immune regulation in the lamina propria. They
proliferate poorly when stimulated with mitogen or specific antigens, but produce high levels
of cytokines upon stimulation (Mowat 2003). Some of these activated CD4+ cells are true
effector cells that help B-cells to produce IgA, while others are “effector memory” cells. A
fraction of CD4+ T-cells are regulatory cells that maintain local tolerance to the load of
harmless lumenal antigens (Sakaguchi 2000).
Intraepithelial lymphocytes
The epithelium contains a unique population of lymphocytes, the so called intraepithelial
lymphocytes (IEL), which are separated from the intestinal lumen only by the tight junctions
of the epithelial cells (Ferguson and Murray 1971). The majority of IELs are T-cells, of
which 80-90% are CD8+, and there are very few B-cells or natural killer (NK) cells in the
epithelium. Of the T-cells 90% express the αβTCR, and about 50% express CD45R0,
suggesting that they are antigen-primed memory cells (Brandtzaeg et al. 1989a).
Approximately 10% of the IELs in the normal small intestine are γδTCR positive (Spencer et
al. 1989), of which a large proportion are double negative cells (CD4-CD8-). It has been
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suggested that a portion of the γδTCR+ T-cells mature extrathymically in the gut mucosa,
resulting in the relative large amount of these unique cells in the gut mucosa (Guy-Grand and
Vassalli 2002).
T-helper 1 and T-helper 2 cells
Almost two decades ago Mosmann et al. discovered that naïve mouse CD4+ T-helper
lymphocytes differentiated into two distinct subsets with different functions and cytokine
profiles upon antigenic stimulus (Mosmann et al. 1986). Later, this was also described in
humans (Wierenga et al. 1991). Murine T-helper 1 (Th1) cells produce in addition to IFN-γ,
also interleukin-2 (IL-2), tumour necrosis factor-α (TNF-α) and lymphotoxin (LT, also
known as TNF-β), that mediate delayed type hypersensitivity responses and activation of
macrophages. The main Th2 cytokine is IL-4, but Th2 cells also secrete IL-5, IL-9, IL-10 and
IL-13. These cytokines provide help for B-cells and are critical in allergic responses
(Mosmann and Sad 1996). The secretion of IFN-γ by Th1 cells inhibits Th2 cells, whereas the
secretion of IL-4 by Th2 cells reciprocally inhibits Th1 cells (Figure 2) (reviewed by Ho and
Glimcher 2002).
Although a distinct Th1/Th2 cytokine profile is not as clear in humans as in animal
cells, an inverse relation remains between the tendency of T-cells to produce IFN-γ, as
opposed to IL-4 and IL-5 (MacDonald and Monteleone 2001). The synthesis of IL-2, IL-6,
IL-10, and IL-13 is not as tightly restricted to a single subset as in mouse T-cells, and both Th
classes produce granulocyte-macrophage colony stimulating factor (GM-CSF), TNF-α, and
IL-3 (Mosmann and Sad 1996). Even though the simultaneous production of IL-2, IL-4, and
IFN-γ has also been observed in human T-helper cells (Paliard et al. 1988), the majority of T-
cell clones and in vivo immune responses show a clear dichotomy between IL-2, IFN-γ, and
TNF-β vs. IL-4 and IL-5. Therefore, the Th1/Th2 dichotomy is still considered an important
functional division in the immune system.
Recently, two additional subsets of in vitro-derived regulatory T-cell types were
identified and named Th3 and Tr1 (T-regulatory 1 cells). Th3 cells secrete mainly
transforming growth factor-β (TGF-β) and to a lesser extent IL-4 and IL-10 (Chen et al.
1994, Fukaura et al. 1996), while Tr1 cells secrete IL-10, low levels of TGF-β, but no IL-4
(Groux et al. 1997) (Table 1). These cells may be important in actively suppressing or
terminating immune responses and are thus linked to the development of oral tolerance.
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Figure 2. Overview of Th1 and Th2 cell differentiation. Naïve CD4+ T-cells are activated via the
TCR upon antigen encountering. When activated, IL-4 receptor (IL-4R) positive Th0 cell starts to
proliferate, secrete IL-2 and express the IL-12 receptor (IL-12R). Signals that influence the
differentiation in a positive way are indicated by arrows, and inhibitory signals are indicated by blunt
arrows. The characteristic chemokine receptors, secreted cytokines, and type of action of the two cell
types are indicated on the bottom of the cartoon. (Modified from Ho and Glimcher 2002, Alam and
Gorska 2003).
T-cells that are resting do not transcribe cytokine genes, but when the T-cell is
activated upon stimulation through the TCR and costimulatory receptors, the transcription of
cytokine genes is rapidly induced (reviewed in Ho and Glimcher 2002). Th1 and Th2 cells
appear to derive from a common precursor Th0 cell that expresses the IL-4 gene (Kamogawa
et al. 1993). Naïve Th0 cells produce primarily IL-2, but may also produce cytokines
characteristic of both Th1 and Th2 lymphocytes. The dose of the antigen, strength of the
signal through the TCR, and costimulation all influence on the Th differentiation, but the
most potent determinant is the cytokine milieu itself around the cell (Figure 2) (Ho and
Glimcher 2002). IL-12 promotes IFN-γ production and Th1 development via signalling
pathways that lead to activation of STAT-4 (signal transducer and activator of transcription
4) and the induction of T-bet, which promotes the Th1 lineage commitment. Ligation of the
IL-4 receptor (IL-4R) expressed on naïve T-cells by IL-4 activates STAT-6 and initiates the
Th2 differentiation program through the transcription factor GATA-3 (reviewed by Ho and
Glimcher 2002).
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Table 1. T-helper cell subtypes classified by their cytokine production
Th subset Cytokines Differentiation factors Suppresses
Th0 IL-2
Th1 IFN-γ, TNF-β,
TNF-α, GM-CSF, IL-2, IL-3, IL-10, IL-13
IL-12, IL-18, IFN-γ
T-bet, STAT-4
Th2
Th2 IL-4, IL-5, IL-9, IL-25
TNF-α, GM-CSF, IL-2, IL-3, IL-10, IL-13
IL-4, IL-13
GATA-3, STAT-6
Th1
Th3 TGF-β, IL-10, IL-4 Th1/Th2
Tr1 IL-10, TGF-β Th1
Abbreviations: GATA, transcriptional factor binding to the nucleotide sequence element GATA; GM-
CSF, granulocyte-macrophage colony stimulating factor; IFN, interferon; IL, interleukin; T-bet, T-
box transcription factor expressed in T-cells; TGF, transforming growth factor; TNF, tumour necrosis
factor; STAT, signal transducer and activator of transcription. (Modified from Alam and Gorska
2003, Borish and Steinke 2003).
B-lymphocytes
B-lymphocytes develop from the same pluripotent stem cells as T-cells, but they mature in
the bone marrow. B-cell recognises antigen with antibody molecules as its receptor. Before
they encounter antigen, B-cells coexpress immunoglobulin M (IgM) and IgD antibodies on
their cell surface, but as they mature they switch to the use of IgG, IgA or IgE surface
receptors. When the B-cells are activated they proliferate and differentiate into plasma cells
that secrete antibody which has the same specificity as that of the epitope bound cell-surface
receptor. The plasma cells have a half-life of only a few days, but part of them further
differentiate into long-lived memory cells (Brandtzaeg et al. 1989b, Farstad et al. 2000).
In the Peyer's patch the antigen is presented by B-cells, dendritic cells or macrophages
to T-cells and the induction of IgA occurs. When CD40 ligand on activated T-cell is bound to
its receptor, CD40, on the surface of the B-cell, an activation signal is mediated in the B-cell
and immunoglobulin class switching starts. Various cytokines secreted by the T-cell also help
in the activation of the B-cell. IL-4 induces B-cell switch to IgE and IgG4 (Pene et al. 1988),
whereas TGF-β in combination with IL-10 induces switch to IgA1 and IgA2 (Defrance et al.
1992). Following IgA switch the B-cells migrate from the PP into the lamina propria,
similarly to T-cells, where the final maturation of IgA B-cells into plasma cells occurs. It has
been shown that production of IgA correlates with the presence of antigen-specific Th2 cells
in the gut mucosa. Thus, mucosal IgA responses probably require Th2, but not Th1
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responses. B-cells can, on the other hand, also influence the differentiation of Th1 vs. Th2
cells by their own cytokine secretion (Harris et al. 2000).
The humoral immune response in the GALT is characterised by the production of
secretory IgA (Mestecky et al. 1991). B-cells comprise about 15-40% of mononuclear cells in
the normal small intestinal lamina propria. Most of them are IgA producing, but low numbers
of IgG and IgM plasma cells are also present (Savilahti 1972, Farstad et al. 2000). Two
distinct IgA subclasses exist, IgA1 and IgA2. IgA1 predominates in the proximal and IgA2 in
the distal part of the intestine (Brandtzaeg et al. 1989b).
Epithelial cells
The mucosal surface is covered with a single layer of polarised epithelial cells, with
undifferentiated, actively proliferating cells at the crypt bottom and mature, absorptive villous
enterocytes at the villous surface. In addition to its barrier function and nutrient uptake, the
intestinal epithelial cell has a variety of immunologic functions (reviewed in Pitman and
Blumberg 2000). The epithelial cells play a crucial role in the uptake and transport of
secretory IgA into the lumen (Mestecky et al. 1991), and they have been shown to express a
variety of cytokines, such as IL-1β, TNF-α, IL-8, IL-10 (Lundqvist et al. 1996, Autschbach
et al. 1998, Daig et al. 2000). Epithelial cells also express receptors for a variety of cytokines,
e.g. IL-1R, IL-2R, IL-4R, IL-7R, IL-9R and IL-15R.
The epithelial cells express MHC class II molecules and have also been shown to be
able to process and present antigens to primed T-cells (reviewed in Hershberg and Mayer
2000). Epithelial cells express E-cadherin, which is an important ligand for the mucosal
integrin αEβ7 expressed on lymphocytes (Cepek et al. 1994). Furthermore, epithelial cells
express or can be induced to express intercellular adhesion molecule-1 (ICAM-1, also known
as CD54), lymphocyte function-associated antigen-3 (LFA-3), and B7-2 (CD86).
Macrophages
Monocytes and macrophages are the major APCs present in blood and peripheral lymph
nodes. They are derived from myeloid progenitor cells in the bone marrow. After migration
into tissues, monocytes differentiate into resident macrophages that may remain in the tissue
for a period of days to months. The gastrointestinal tract contains also the largest number of
macrophages of any tissue of the body (Stumbles et al. 1999). In addition to their antigen-
presenting capability they activate T-cells through their production of accessory cytokines.
The macrophages in the gut are quite heterogeneous and are more abundant in the small
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intestine than in the large intestine. By immunohistochemical studies they have been shown
to locate in the villous core, the subepithelial space in the crypts, under the dome epithelium
overlying Peyer's patches and in the patch itself (Golder and Doe 1983). Macrophages secrete
cytokines like IL-1, IL-6, IL-8, IL-10, IFN-γ, TNF-α, and TGF-β and express receptors for
IFN-γ, IL-4, IL-10, and TNF-α. They also express various adhesion molecules, as well as
HLA class II molecules (reviewed in Stumbles et al. 1999).
2.3 Mucosal immune responses and oral tolerance
Oral exposure to dietary antigens by the immune system normally leads to antigen specific
tolerance. This phenomenon has been termed oral tolerance and can be induced by the
majority of soluble antigens (Mowat 2003). Substances that do not induce oral tolerance are
bacterial polysaccharides and toxins that induce active immunity. The immunogenic immune
response leads to the activation of Th1 or Th2 cells and is necessary for host defence against
mucosal pathogens. The uptake of harmless antigens by APC and their presentation to T-cells
is thought to lead to a short-lived Th1-type response, which is superseded by the induction of
Th3 cells producing suppressor cytokines such as TGF-β, IL-4 and IL-10 (Figure 3). The Th3
cells migrate to the lamina propria, where they regulate the potentially injurious Th1 response
(reviewed in Strobel 2002, Mowat 2003). The release of suppressive cytokines may also
induce “bystander” effects; their release into the microenvironment may suppress an ongoing
immune response to an unrelated, but anatomically colocalised antigen. It has been postulated
that suppressor cells are the major players in the development and maintenance of oral
tolerance to food antigens as well as to normal gut flora (Sakaguchi 2000). A unique
population of naturally occurring suppressive CD4+CD25+ T-cells was originally identified in
mice (Sakaguchi et al. 1995), and later also in humans (Jonuleit et al. 2001). CD4+CD25+ T-
cells require cell to cell contact, and it was recently suggested that they block the proliferation
of the responder cell by their surface membrane-bound TGF-β (reviewed in Chen and Wahl
2003). It is still unknown how these CD4+CD25+ cells relate to in vitro-derived Tr1 and Th3
cells.
The above is however, a simplified picture of oral responsiveness and
nonresponsiveness. Based on animal studies the nature and dose of the antigen, the route of
entry, and the timing of the antigen encounter are critical in determining the immune reaction.
In addition, the age of the host, genetic background, and pre-existing inflammation in the
GALT further influence the outcome (Strobel 2002). Feeding low-doses of an antigen favours
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active suppression caused by regulatory T-cells in the PP, while feeding high-doses favours
clonal deletion or anergy (Strobel 2002). Clonal anergy (i.e. inactivation) of antigen specific
T-cells develops when APCs do not provide a costimulatory signal. The anergic T-cells
remain intact but are incapable of proliferating or secreting IL-2 (Figure 3).
Figure 3. Immunoregulation after orally administered antigen; induction of tolerance versus
inflammation. In the physiological situation, mucosally encountered antigens induce oral tolerance of
lamina propria and intraepithelial lymphocytes as there is no activating costimulatory signal on MHC
class II positive antigen-presenting cells (APC). This leads to anergy or deletion of CD4+ T-cells, or to
suppression of other antigen-reactive cells via the production of inhibitory cytokines (e.g. TGF-β) by
Th3 regulatory cells. In contrast, in inflammation the antigen presentation in association with HLA
class II antigens leads to activation of CD4+ Th0 cells and the induction of Th1 and memory cell
subtypes. (Modified from Strobel 2002).
Oral tolerance has been demonstrated to develop in humans to keyhole limpet
hemocyanin (Husby et al. 1994), but otherwise the development of oral tolerance in humans
is poorly documented. The normal response in Peyer's patches to food antigens (bovine β-
lactoglobulin) in humans was shown to be predominated by Th1-type cytokine secreting
cells, which is contradictory to the findings in rodents that typically show a local Th2/Th3
response following oral antigen feeding (Nagata et al. 2000). Multiple sclerosis patients fed
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myelin basic protein had increased numbers of short lived T-cells producing TGF-β in the
peripheral blood than patients who received placebo, suggesting suppressor activity (Fukaura
et al. 1996). Another study with healthy volunteers found no expression of IL-2 mRNA in
peripheral blood mononuclear cells (PBMC) when stimulated with ovalbumin or bovine γ-
globulin, suggesting that anergy is the major mechanism for oral tolerance in humans (Zivny
et al. 2001). This points to the fact that only little is known about the factors that influence the
induction of oral tolerance in humans and that the results from animal studies can not directly
be translated into human studies.
2.4 Oral tolerance in autoimmune diseases
Autoimmune diseases result from a combination of genetic, immunologic, hormonal, and
environmental factors. Studies over the past years have suggested that there is an association
between a preceding inflammation and autoimmune disease. The factors that trigger
inflammation could include viruses, bacterial infection and mechanical injury (reviewed by
Wucherpfennig 2001, Bach 2003). Infectious agents may induce the breakdown of
immunological tolerance and the appearance of autoreactivity. However, the specific
relationship between infection and autoimmunity is still unclear. One of the mechanisms
responsible could be molecular mimicry, i.e. the presence of shared epitopes between
infectious and self antigens, whereby epitopes on microbial agents stimulate the production
of antibodies and the proliferation of T-cells that react with self antigens (reviewed by
Karlsen and Dyrberg 1998).
The responses in autoimmune disorders have features of a Th1-type response,
suggesting that defective T-cell tolerance underlies the disorder (recently reviewed by Hill
and Sarvetnick 2002). Tissue destruction in autoimmune diseases has been associated with
the presence of pro-inflammatory cytokines, such as IFN-γ, TNF-α, and IL-1. However, these
cytokines have also shown ability to suppress inflammation by homeostatic mechanisms,
indicating that the original distinction between Th1 cells as pathology producing and Th2
cells as therapeutic is not as clear cut as previously believed (Hill and Sarvetnick 2002).
Allergies and atopic diseases represent an overly aggressive Th2-type response leading to
hypersensitivity to a broad spectrum of normally encountered antigens. Previously it was
thought that a Th2-type response protected against development of autoimmune diseases, but
two recent epidemiological studies suggest that patients with a Th1 illness are more likely to
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have a Th2 illness, suggesting that they have a common underlying aetiology (Kero et al.
2001, Simpson et al. 2002).
The therapeutic efficiency of oral tolerance induction in various animal models of
human diseases is well documented in models of multiple sclerosis, diabetes, arthritis,
myasthenia gravis, thyroidits, and colitis (reviewed by Krause et al. 2000, Spiekermann and
Walker 2001). In addition, a recent study in an animal model of human coeliac disease
showed that intranasal administration of recombinant alpha-gliadin downregulated the
immune response to wheat gliadin in DQ8 transgenic mice (Senger et al. 2003). Initial studies
of treatment of autoimmune diseases in humans have already been reported, but the results
have been equivocal at best (Spiekermann and Walker 2001).
3. ADHESION MOLECULES
Trafficking of lymphocytes in the intestinal mucosa is a complex multi-step process. It is
mediated by adhesion molecules, the homing receptors on lymphocytes and their
counterreceptors, termed vascular addressins, on the endothelial cells in specialised
postcapillary high endothelial venules. Different combinations of these adhesion molecules
ensure tissue-specific migration. The selective recruitment of lymphocytes makes the
immune response more efficient by directing the cells back to the location where they first
encountered their antigen and where they thus are more likely to meet their specific antigen
again (Picker 1994).
Cells can express adhesion molecules constitutively or they can be upregulated by
cytokines, chemokines or other proinflammatory molecules such as complement activation
products or microbial metabolites. In addition to mediating adhesion, some of these
molecules are also costimulatory during intercellular signalling. According to their structure
and function, adhesion molecules can be divided into three different families: selectins,
integrins, and Ig superfamily adhesion molecules. The selectins participate in the process of
leukocyte rolling along vascular endothelium, whereas the integrins and Ig superfamily
adhesion molecules are important for stopping leukocyte rolling and mediating
transendothelial migration (Springer 1994).
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3.1 Homing receptors in the gut
A number of cell adhesion molecules have been implicated in the selective recruitment of
lymphocytes in the intestine, of which the α4β7-MAdCAM-1 integrin-addressin pair is the
most important (Salmi and Jalkanen 1999).
α4β7- and αEβ7-integrins
The β7-integrin chain can be expressed as a heterodimer with α4 or αΕ. α4β7-integrin is
thought to be a key lymphocyte homing receptor in flat venules in lamina propria (Berlin et
al. 1993). This integrin is thought to be the primary ligand for the MAdCAM-1 vascular
receptor, which normally is expressed exclusively in the gastrointestinal mucosa (Berlin et al.
1993). α4β7-integrin also binds to vascular cell adhesion molecule-1 (VCAM-1). α4β7-
integrin is expressed on most resting lymphocytes and can be activated by a variety of
stimuli, e.g. by chemokines. Both L-selectin and α4β7 participate in activation-independent
rolling of lymphocytes on MAdCAM-1 (Parker et al. 1992, Erle et al. 1994, Rott et al. 1997).
As many as 70% of human lamina propria lymphocytes and 30-50% of IELs are α4β7-
integrin positive (Farstad et al. 1996).
The αEβ7-integrin (HML-1, CD103) is found on up to 90% of IELs, and on 30-50% of
lamina propria lymphocytes (Farstad et al. 1996). It binds to E-cadherin on the epithelial cells
(Cepek et al. 1994) and may be critical in the epithelial localisation of IELs (Parker et al.
1992).
Mucosal addressin cell adhesion molecule-1 (MAdCAM-1)
MAdCAM-1 is a key addressin for intestinal tissues (Streeter et al. 1988). It belongs to the
immunoglobulin family and is related to other vascular adhesion molecules such as VCAM-1
and ICAM-1. MAdCAM-1 is selectively expressed on postcapillary venules in the Peyer's
patches and in mesenteric lymph nodes, directing lymphocyte migration to intestinal lamina
propria and into intestine-associated lymphoid tissues (Briskin et al. 1997). It has been shown
to be involved e.g. in the lymphocyte migration into the inflamed pancreas in NOD mice
(Yang et al. 1997).
Lymphocyte function-associated antigen 1 (LFA-1)
LFA-1 (αLβ2, CD11a/CD18) is a multifunctional adhesion molecule involved in the antigen
presentation process and T-cell mediated killing (Fischer et al. 1986). It is expressed on most
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circulating leukocytes, and is the only integrin that is significantly expressed on lymphocytes
(Fischer et al. 1986). It is involved in the later steps of the adhesion cascade, which allows the
cell to arrest on the endothelial cell and transmigrate into mucosal sites (Springer 1994). It
binds to the intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) on
endothelial cells.
Intercellular adhesion molecule-1 (ICAM-1)
ICAM-1 (CD54) is a member of the immunoglobulin superfamily and widely expressed on
vascular endothelial cells throughout the body (Boyd et al. 1988). The expression of ICAM-1
can be up-regulated by inflammatory mediators on a variety of cells, including intestinal
epithelial cells and APCs. It mediates the later steps in the adhesion cascade by binding to
LFA-1 (Springer 1994). The ICAM-1/LFA-1 interaction is critical for establishing a cell to
cell contact between APC and T-cells, leading to T-cell activation (Springer 1994).
3.2 Alterations in lymphocyte recruitment during intestinal inflammation
During inflammation the same principles apply to lymphocyte migration as during
physiological circulation. Cytokines and other mediators affect the expression of adhesion
molecules at site of inflammation, thus controlling the traffic of leukocytes to tissue. As some
of the molecules are up-regulated fast, whereas the appearance of others may take hours or
even days, it is thought that this determines the cell composition seen at sites of inflammation
at different time points. Immunohistological studies of lymphocyte trafficking indicate that
gut inflammation induces dramatic changes in the extent of lymphocyte recruitment to the
intestinal mucosa. Severe inflammation seems to induce additional recruitment mechanisms,
as well as a superinduction of MAdCAM-1 and ICAM-1 expression. However, recruitment of
T-cells to the gastrointestinal tract remains largely selective for α4β7+ cells also during
inflammation (Briskin et al. 1997, Salmi and Jalkanen 1999).
4. MEDIATORS OF INFLAMMATION
Mediators of inflammation include cytokines, chemokines, complement activation products,
immunoglobulins and acute-phase proteins.
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4.1 Cytokines
Cytokines are a large group of low-molecular-weight soluble proteins that act as messengers
both within the local immune system and between the immune system and other systems in
the body (Table 2). Which cytokines are produced in response to an immune insult
determines initially whether the response is cytotoxic, humoral, cell-mediated, or allergic
(reviewed in Borish and Steinke 2003). Cytokines mediate their effects through binding to
their receptors, which activates intracellular signals (reviewed by Ho and Glimcher 2002).
Any cytokine may have many different biological effects depending on the target cell, and
different cytokines may have similar effects. Cytokines produced by leukocytes that affect
mainly other white cells are termed interleukins. Cytokines are usually divided into
proinflammatory (IL-1, IL-2, IL-6, IL-12, IL-18, IFN-γ, and TNF-α), anti-inflammatory (IL-
4 and IL-13), and immunosuppressive (IL-10, TGF-β), based on their activity.
IL-1α
Interleukin-1α is a proinflammatory cytokine. It belongs to the IL-1 family, which consists of
four peptides; IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), and IL-18 (Dinarello 2002).
IL-1α and IL-1β have similar biological effects and they bind with similar affinities to the
two IL-1 receptors (Dinarello 1988). Type I receptor transduces the biological effects of IL-1,
while the type II receptor, which is expressed on B-cells, neutrophils and bone marrow cells,
has an anti-inflammatory function and is therefore referred to as a decoy receptor (Sims et al.
1993). Both receptors exist in membrane-bound and soluble forms. The naturally occurring
IL-1Ra produced by monocytes can bind to IL-1 type I receptor with similar affinity as IL-1α
and IL-1β, without transducing the biological activity and hence functions as a cytokine
antagonist (Dinarello 2002). IL-1Ra is secreted in inflammatory processes and is thought to
modulate the harmful effects of IL-1 in the natural course of inflammation. The production of
IL-1Ra is upregulated by many cytokines such as IL-4, IL-6, IL-13 and TGF-β.
IL-1α is mainly produced by monocytes and macrophages, but also by T-cells, B-cells,
neutrophils, and endothelial cells. The production may be stimulated by endotoxins, other
cytokines, microorganisms, and antigens. IL-1α, as well as IL-1β, are synthesised as inactive
precursors of 31 kDa (Dinarello 1988). The mature and active 17.5 kDa form is obtained
through cleavage by a serine protease, termed interleukin converting enzyme (Cerretti et al.
1992).
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Table 2. Major cytokines and their activities
Cytokine Main cell source Major activities
IL-1 Macrophages Activates T-cells and macrophages, induces inflammatory
response
IL-2 T-cells Activates T-cells, NK cells and macrophages
IL-4 Th2 cells Activates Th2 cells and IgE class switching, inhibits Th1
cells
IL-5 Th2 and mast cells Induces differentiation of B-cells and eosinophils
IL-6 Th2 cells, macrophages,
fibroblasts
Activates lymphocytes and antibody production, induces
acute phase responses
IL-10 CD4+ T-cells Inhibits Th1 cells and production of proinflammatory
cytokines, stops antigen presentation
IL-12 Macrophages, B-cells,
and dendritic cells
Induces Th1 cells and stimulates production of IFN-γ
IL-18 Macrophages Activates Th1 cells
IFN-γ Th1 and NK cells Activates Th1 cells, macrophages, class II MHC and
adhesion molecules. Inhibits Th2 cells
IFN-β Fibroblasts, virally
infected cells
Induces resistance of cells to viral infections
TNF-α Macrophages and
lymphocytes
Activates macrophages, PMN cells, and endothelial cells,
promotes inflammation
TGF-β T-, B- and mast cells,
macrophages
Immunosuppression, stimulates collagen formation
GM-CSF Lymphocytes and
macrophages
Stimulates granulocytes and monocytes
Abbreviations: GM-CSF, granulocyte-macrophage colony stimulating factor; IFN, interferon; IL,
interleukin; MHC, major histocompatibility complex; NK, natural killer; PMN, polymorphonuclear;
TGF, transforming growth factor; TNF, tumour necrosis factor. (Modified from Delves and Roitt
2000b, Borish and Steinke 2003).
IL-1α has many biological functions. It activates T-cells by inducing the production of
IL-2 and expression of IL-2 receptors. It also enhances the expression of LFA-1 on T-cells
and stimulates the adherence of leukocytes to endothelial cells by upregulating ICAM-1,
VCAM-1 and E-selectin. IL-1α acts also as a chemoattractant and acts on macrophages in an
autocrine way to induce the synthesis of other proinflammatory products. IL-1α is
responsible for many of the symptoms associated with being ill. It interacts with the central
nervous system to cause fever, lethargy, sleepiness and anorexia. It activates the synthesis of
acute phase proteins, such as C-reactive protein and complement components by the liver. It
also contributes to the hypotension of septic chock (reviewed by Dinarello 2002).
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IL-2
IL-2 was originally designated as the “T-cell growth factor” because of its ability to stimulate
proliferation of naïve T-cells (Morgan et al. 1976). IL-2 is produced by T-cells, mainly CD4+,
but also by CD8+ T-cells, and natural killer (NK) cells (Malek 2003). It is the most powerful
growth factor and activator for T-cells and promotes their maturation and the production of
proinflammatory cytokines such as IFN-γ and TNF-α. It also induces growth and
differentiation of B-cells and activates macrophages, NK cells, γδTCR+ IELs and cytotoxic
T-cells (Schimpl et al. 2002, Malek 2003). IL-2 has recently been suggested to have
immunosuppressive effects as well by promoting the development of CD4+CD25+ regulatory
cells (Sakaguchi et al. 1995).
IL-2 receptor (CD25)
The IL-2 receptor is a multichain receptor composed of three subunits: β and γ-chains which
are members of the haematopoietic cytokine receptor family with Ig-like domains, and the
structurally unrelated α-chain (Waldmann 1991). The hematopoietin receptor superfamily
includes receptors for erythropoietin, IL-3, IL-4, IL-7, GM-CSF, growth hormone and
prolactin. The stimulation of T-cells by antigen in the presence of accessory signals it leads to
the simultaneous secretion of IL-2 and the expression of high-affinity IL-2 receptors. The
receptor is upregulated by antigen stimulation or by IL-2 on T-cells and IFN-γ on
macrophages. Therefore, CD25, which is the α-chain of the IL-2 receptor, is widely used as
an activation marker for mature lymphocytes.
IL-4
IL-4 is the major Th2 cytokine and produced by Th2 cells, NK cells, basophils, eosinophils
and possibly mast cells (Paul and Ohara 1987, Lorentz and Bischoff 2001). IL-4 drives the
initial differentiation of naïve Th0 cells toward a Th2-type and inhibits the proliferation of
Th1 cells. It acts on B-cells to induce activation and differentiation, leading to the production
of IgG1 and IgE. As a result of its ability to stimulate IgE production it takes part in mast cell
sensitisation and thus in allergy and in the defence against helminthie infections (Del Prete et
al. 1988).
IL-4 has pleiotropic effects. IL-4 shares with IL-10 the anti-inflammatory features; they
inhibit macrophage activation, T-cell proliferation, the production of IL-1α, IL-1β, TNF-α,
and IL-6 by monocytes, and production of TNF-α and TNF-β by T-cells. Therefore, IL-4
may play a role in suppressing inflammatory processes mediated by these cytokines. IL-4
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increases the expression of MHC class II molecules, IL-1Ra and TNF-R. IL-4 production can
be induced by IL-2 and IL-4, and suppressed by TGF-β and IFN-γ (Lorentz and Bischoff
2001). The IL-4 receptor is a heterodimer, of which one chain is shared with IL-2R and IL-
13R.
IFN-γ
IFN-γ is produced by Th1 cells and NK cells and is the major positive regulator of Th1-type
response (reviewed in Farrar and Schreiber 1993). It belongs to the interferon family, also
including IFN-α and IFN-β, which are produced by a variety of cells upon virus infection
(reviewed in Farrar and Schreiber 1993). Type I interferons (IFN-α and IFN-β) bind to a
common receptor, which is distinct from the one used by the type II interferon, IFN-γ. The
receptor for IFN-γ is present on almost all cell types except mature erythrocytes (Farrar and
Schreiber 1993).
IFN-γ stimulates antigen presentation, cytokine production and other effector functions
of monocytes. This results in the accumulation of macrophages at the site of cellular immune
responses and their activation to kill intracellular pathogens. IFN-γ also stimulates killing by
NK cells and neutrophils. Production of IFN-γ is mainly induced by IL-12 and IL-18, which
are secreted by monocytes and macrophages. IFN-γ induces the expression of MHC class II
molecules (Skoskiewicz et al. 1985) and ICAM-1. IFN-γ stimulates the production of IgG2
and IgG3 subclass antibodies by B-cells. It also stimulates the production of IFN-β, IL-1α,
IL-1β, TNF-α, and IL-12 (Mühl and Pfeilschifter 2003). It suppresses Th2 responses by
inhibiting IL-4 and IL-10 production by macrophages (Pene et al. 1988).
TNF-α
Tumour necrosis factor was originally described as a factor that could kill tumour cells in
vitro (Old 1985). A mature 17 kDa form is cleaved from the membrane associated TNF-α
form by TNF-α converting enzyme. In the circulation TNF-α is mostly detected in a trimeric
form (reviewed in Papadakis and Targan 2000). TNF-α acts via two different receptors
TNFRI (p55) and TNFRII (p75), which are encoded by separate genes. The receptors are
shared by TNF-β (LT, lymphotoxin), and the receptors have similar affinities for both TNF
factors. The receptors belong to a family of proteins called the TNF and nerve growth factor
receptor family, that includes the B-cell antigen CD40, CD27, and Fas antigen (reviewed in
Papadakis and Targan 2000). Binding of Fas ligand to Fas initiates programmed cell death,
apoptosis (Nagata and Golstein 1995).
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TNF-α is produced mainly by macrophages and monocytes, and to a lesser extent by
NK cells, T-cells, B-cells, and mast cells. Its major effect is promotion of inflammation and
its effects overlap with the effects of IL-1. The responses include fever, shock, tissue injury,
tumour necrosis, synthesis of collagen and proliferation of fibroblasts, and apoptosis. TNF-α
also induces the production of IL-1 and IL-6. TNF-α induces ICAM-1 and VCAM-1
expression on endothelial cells, which attract circulating leukocytes to the inflammatory loci
(Papadakis and Targan 2000).
The pathogenic role of TNF-α has been implicated in many chronic inflammatory
processes such as coeliac disease, rheumatoid arthritis, graft-versus-host disease, and Crohn's
disease (reviewed in Andreakos et al. 2002). Treatment with monoclonal antibodies against
TNF-α (e.g. infliximab) has been beneficial in randomised, double-blinded clinical trials in
rheumatoid arthritis and in severe cases of Crohn's disease (Andreakos et al. 2002). Recently,
a successful treatment of a patient with refractory coeliac disease with TNF-α antibodies was
also reported (Gillett et al. 2002).
4.2 Chemokines and chemokine receptors
Chemokines are a group of small (8-14 kD) chemotactic cytokines that regulate the migration
of leukocytes from the blood into tissues. Today there are some 50 chemokines and over 20
chemokine receptors identified (recently reviewed by Ono et al. 2003). Chemokines are
classified according to the position of two cysteine (C) residues compared with the other
amino acids (X) near the NH2-terminal. The four chemokine subgroups are CXC (α-
chemokines), CC (β-chemokines), C, and CX3C (Zlotnik and Yoshie 2000). Generally, CXC
chemokines attract neutrophils, whereas the CC chemokines are less selective and attract
lymphocytes, monocytes, basophils, and eosinophils.
Chemokines are produced by virtually all cells upon activation with proinflammatory
cytokines or bacterial products. Chemokine receptors are found on all leukocytes. Each type
of leukocyte bears chemokine receptors that guide it to particular chemokines in the tissue.
Naïve T-cells express receptors CXCR4 and CCR7, whereas memory and effector cells
express CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CXCR5, and CCR9 (reviewed in Rossi
and Zlotnik 2000). Chemokine receptors are G-protein coupled, seven-transmembrane
receptors. Chemokines and their receptors are not only involved in the control of
hematopoietic cell migration and Th1 and Th2 development, but also in a wide variety of
other physiological and pathological processes, such as lymphoid organ development, wound
REVIEW OF THE LITERATURE
___________________________________________________________________________
29
healing, angiogenesis, and metastasis (Rossi and Zlotnik 2000). Recently it was discovered
that Th1 and Th2 cells have a diverse expression of surface antigens; Th1 cells preferentially
express the CXCR3 and CCR5 chemokine receptors, while Th2 cells express chemokine
receptors CCR3, CCR4, and CCR8 (Annunziato et al. 1999).
CCR4
The chemokine receptor CCR4 was originally reported to be a selective marker for Th2 cells
(Bonecchi et al. 1998, Sallusto et al. 1998), but recently it was shown to be expressed also on
skin homing Th1 and Th2 cells (Campbell et al. 1999). Thereby, its role in Th2 responses still
needs to be clarified. It is possible that whereas CCR3 may be a marker for IL-4 producing
Th2 cell, CCR4 and CCR8 may be expressed more widely in Th2 polarised populations.
CCR-4 is a receptor for ligands CCL17 (TARC, thymus- and activation-regulated
chemokine) and CCL22 (MDC, macrophage derived chemokine). CCR-4 is also expressed
on NK cells and immature dendritic cells, and is involved in dendritic cell trafficking and T-
cell migration from tissue to lymph nodes (Campbell et al. 1999). CCR-4 expressing cells are
not found in the normal small intestine, but CCR-4 expressing cells have been described in
inflammatory bowel disease patients (Agace et al. 2000).
CCR5
The chemokine receptor CCR5 is the receptor for ligands CCL3 (MIP-1α, macrophage
inflammatory protein 1α), CCL4 (MIP-1β, macrophage inflammatory protein 1β) and CCL5
(RANTES, regulated on activation normal T-expressed and presumably secreted). The
expression of CCR5 is biased to Th1 cells (Bonecchi et al. 1998, Loetscher et al. 1998,
Sallusto et al. 1998). It is also expressed on monocytes and dendritic cells, and involved in
the migration of Th1 cells and macrophages to sites of inflammation.
Normal small intestinal lymphocytes both in the epithelium and in the lamina propria
have been shown to express CCR5 and CXCR3, but not CCR4 (Agace et al. 2000). CCR-5
was also expressed on peripheral blood lymphocytes expressing the β7-integrin, suggesting a
role for CCR-5 in the selective migration of lymphocytes to the intestine (Agace et al. 2000).
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5. CLINICAL ASPECTS OF IMMUNOLOGIC INFLAMMATION IN
THE SMALL INTESTINE
Immunologically mediated enteropathies consists of a group of different diseases that are
characterised by a varying degree of villous destruction in the small intestine. Although the
underlying immune mechanisms differ in the various conditions, they share a final effector
pathway: activated T-cells producing cytokines that ultimately affect the villous architecture.
In agreement with this, activated T-cells have been shown to cause villous atrophy in cultured
explants of human foetal small intestine (MacDonald and Spencer 1988). The prototypic
disorder in this group is coeliac disease (CD).
5.1 Coeliac disease
Coeliac disease is a chronic autoimmune disease in the small intestine that is triggered by
dietary gluten (Farrell and Kelly 2002). Previously the prevalence of coeliac disease was
estimated to be 1:1000, but screening studies identifying asymptomatic CD patients report
prevalences of 1:99-1:300 in Europe (Catassi et al. 1994, Collin et al. 1997, Johnston et al.
1997, Mäki et al. 2003). Recent screening studies suggest that the rate may be the same in the
USA (Not et al. 1998, Fasano et al. 2003). CD has a strong genetic predisposition.
Approximately 90% of CD patients carry the HLA class II HLA-DQ2 heterodimer
(DQA1*05-DQB1*02), and most of the remaining patients carry HLA-DQ8 (DQA1*0301-
DQB1*0302) (Sollid 2002). However, other genetic factors are involved because up to 35%
of the Caucasian population express HLA-DQ2. The disease risk is approximately 10% in
healthy first-degree relatives of CD patients (Mäki et al. 1991, Mustalahti et al. 2002) and the
concordance between monozygotic twins has been suggested to be as high as 75-80%
(Hervonen et al. 2000, Greco et al. 2002).
Dermatitis herpetiformis (DH), a blistering skin disease with pathognomic granular IgA
deposits in the skin, is one manifestation of CD (Fry et al. 1973). In most of the patients with
DH, villous atrophy identical with that of CD is found, although it is mostly less severe and
affects a shorter length of intestine than CD (Fry et al. 1973, Reunala et al. 1984).
Symptoms and diagnosis
The spectrum of coeliac disease has widened from the classical form of steatorrhoea and
malabsorption in infants, towards milder forms in older children and adults. Paediatric
patients may present with impaired growth, anaemia, or pubertial delay and totally lack
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gastrointestinal symptoms. The diagnosis is increasingly made in adults, who may present
with diarrhoea, flatulence, weight loss, or only with minor abdominal discomfort.
A variety of diseases has been reported to occur in association with CD. There is a
well-established association between CD and type 1 diabetes (T1D) (Savilahti et al. 1986)
and selective IgA deficiency (Savilahti et al. 1985, Collin et al. 1992). Other diseases
associated with CD and DH are autoimmune thyroiditis, pernicious anaemia, Sjögren's
syndrome, Addison's disease, rheumatoid arthritis, lupus erythematosus, sarcoidosis, vitiligo,
and alopecia areata (Reunala and Collin 1997, Kaukinen et al. 1999). CD may also be
associated with neurological symptoms, of which the most common were neuropathy,
memory impairment and cerebellar ataxia in a Finnish adult cohort (Luostarinen et al. 1999).
Patients with these associated conditions are often symptomless (called the silent form of
CD) and are found only through screening. Untreated CD has also been associated with an
increased risk for gastrointestinal carcinoma or lymphoma, which can be avoided with a strict
gluten-free diet (Swinson et al. 1983).
The revised diagnostic criteria for childhood CD according to ESPGHAN are
characteristic villous atrophy with crypt hyperplasia and lymphocytic intraepithelial
infiltration in a small intestinal biopsy, and clear improvement or normalisation of serology
and symptoms when on a gluten-free diet (Walker-Smith et al. 1990). CD patients on a gluten
containing diet have increased levels of serum antibodies specific for various antigens,
including gluten and the autoantigen tissue transglutaminase (tTG) (reviewed by Farrell and
Kelly 2002). IgA antibodies against tTG are highly specific and sensitive for coeliac disease,
and thereby greatly assist in the diagnosis of CD, as well as in monitoring the response to a
gluten-free diet (Dieterich et al. 1997, Sulkanen et al. 1998).
Patients with DH have the same association to HLA-DQ and the same autoantibodies
as CD patients. The rash in DH is located most typically to the elbows, the knees and the
buttock. The diagnosis is based on the presence of granular IgA deposits at the dermal-
epidermal junction in the skin by immunofluorescence staining. Like the enteropathy, the
skin lesions respond to a gluten-free diet, although it usually takes months of strict diet before
the symptoms are resolved, and in many patients the gluten-free diet is accompanied by
treatment with the anti-inflammatory agent diaminodiphenylsulfone (dapsone) (Fry et al.
1973, Reunala et al. 1984).
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Potential coeliac disease
Coeliac disease can be symptomless, or clinically silent (Ferguson et al. 1993). It has also
been shown that coeliac disease can develop on previously normal mucosa (Weinstein 1974,
Mäki et al. 1990, Collin et al. 1993, Troncone 1995, Corazza et al. 1996, Troncone et al.
1996b). Patients with such a latent form of CD express a normal jejunal mucosal architecture
while on normal gluten-containing diet, but will later be found to have a flat mucosa, which
heals on a gluten-free diet (Mäki et al. 1990, Corazza et al. 1996, Troncone et al. 1996b).
Latent CD can be suspected in patients with positive coeliac autoantibodies and increased
density of γδTCR+ IELs (Holm et al. 1992, Arranz et al. 1994, Kaukinen et al. 1998).
Additional histological changes compatible with overt CD have also been shown to develop
in these individuals when challenged with gliadin orally or rectally (Troncone et al. 1996a).
Since the term latent CD can be given only retrospectively it has been suggested that
this “precoeliac” state should instead be named potential CD (Ferguson et al. 1993). Potential
CD can be found in healthy family members of patients with CD or DH (Mäki et al. 1990,
Mustalahti et al. 2002), and in patients with type 1 diabetes or other CD associated diseases.
The presence of autoantibodies seems to predict the development of CD (Collin et al. 1993,
Troncone 1995, Kaukinen et al. 1998). In follow-up studies it has been observed that
potential CD progresses to overt CD in up to half of the patients (Collin et al. 1993, Kaukinen
et al. 1998).
Molecular pathogenesis
Current concepts of the pathogenesis of CD include activation of αβTCR+CD4+ T-cells in the
lamina propria and the production of antibodies against a complex of gliadin peptide and
tissue transglutaminase. A key observation was that the T-cells recognise modified,
deamidated gluten peptides that are presented by DQ2 or DQ8 molecules, and that it is the
enzyme tissue transglutaminase that performs the deamidation (Molberg et al. 1998). Tissue
transglutaminase is an intracellular enzyme that is released from fibroblasts, endothelial cells,
and inflammatory cells upon mechanical injury or inflammation. When secreted, tTG can
crosslink glutamine-rich proteins, particularly gluten from wheat. At acidic pH tTG can
deamidate the glutamine residues in gluten to glutamic acid. This posttranslational
modification enhances binding of gluten epitopes to HLA-DQ2 and -DQ8 and potentiates
their ability to stimulate T-cells (Molberg et al. 1998). Recently, it was shown that a 33-mer
peptide fragment from gluten is resistant to digestive processing by proteases and that this
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fragment is an extremely potent antigen for T-cell stimulation. The same fragment was shown
to react with tTG with higher affinity than any other peptide so far (Shan et al. 2002).
The mechanisms that produce the lesions in CD are so far not well known. IELs might
be involved in the lesion formation, but to date, there are no reports of IELs that recognise
gluten in CD. The villous atrophy is instead thought to arise because of activation of IFN-γ
secreting Th1 cells, that initiates production of inflammatory cytokines (Nilsen et al. 1995,
Nilsen et al. 1998). Paradoxically, the major Th1 inducing cytokine, IL-12, has not been
detected in the CD mucosa (Nilsen et al. 1998). IFN-α or IL-18 dependent Th1 activation has
been suggested in recent studies (Monteleone et al. 2001, Salvati et al. 2002), and IFN-α has
also been implicated in the disease process as it has been documented that patients receiving
IFN-α therapy spontaneously develop CD (Monteleone et al. 2001). Th1 cells and
macrophages have also been shown to secrete increased amounts of TNF-α in the coeliac
mucosa (Kontakou et al. 1995a, Nilsen et al. 1998), which also plays a role in the
upregulation of the expression of matrix metalloproteinases and epithelial cell death (Pender
et al. 1997). Increased synthesis of matrix metalloproteinases, which degrade the lamina
propria matrix, is postulated to be one of the factors causing villous atrophy. Another
suggested factor involved in the mucosal remodelling and crypt hyperplasia is keratinocyte
growth factor, which was shown to be overexpressed in CD mucosa (Salvati et al. 2001).
However, the expression of cytokines has not been determined in the potential form of CD,
which could be more informative on the factors causing villous atrophy since the mucosa is
still intact at this stage.
5.2 The gut immune system in type 1 diabetes
Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of insulin-
secreting pancreatic islet β-cells by autoreactive T-cells and their mediators (Atkinson and
Maclaren 1994). Although the exact sequence of events leading to the autoimmune
destruction of islet β-cells is currently not completely known, it is well established that
genetic, environmental, and immunological factors contribute to the pathogenesis (reviewed
in Åkerblom et al. 2002). Finland has the highest incidence of T1D in the world with over 50
new cases / 100 000 children / year. In the Finnish population, the susceptibility for T1D is
strongly associated with the HLA-DQB1*0302 allele (DQ8), and weakly with the DQB1*02
allele (DQ2) (Ilonen et al. 1996). Strong protection from the disease has been associated with
the DQB1*0602 and weak protection with the DQA1*0301 allele (Nejentsev et al. 1999).
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Although the susceptibility is linked to the MHC locus, MHC-identical siblings are only 13%
concordant for T1D. T1D and CD share the same high-risk HLA-DQ2 genotype (DQA1*05
and DQB1*02). Screening of patients with T1D has shown that the prevalence of CD among
children and adults with T1D is as high as 2-8% (Saukkonen et al. 1996, Carlsson et al. 1999,
Hansen et al. 2001, Barera et al. 2002). T1D was on the other hand found in 1.0% of DH
patients and in 5.5% of CD patients in a Finnish cohort (Reunala and Collin 1997).
Activation of the gut immune system in T1D
In addition to the association with CD, recent data suggest that the gut immune system plays
a role in the development of T1D. Several serological studies on patients with newly
diagnosed T1D have reported enhanced immune responses to cow's milk proteins (Savilahti
et al. 1988, Karjalainen et al. 1992, Cavallo et al. 1996, Vaarala et al. 1996), and studies on
infants at genetic risk of T1D indicate that primary immunisation to insulin occurs by
exposure to dietary cow's milk insulin (Vaarala et al. 1998, Vaarala et al. 1999, Paronen et al.
2000). In one study glutamic acid decarboxylase-specific T-cells in patients with T1D were
shown to express the gut-associated homing receptor α4β7-integrin (Paronen et al. 1997),
which suggests that autoreactive T-cells in type 1 diabetes may recirculate between the gut
and the pancreas. Accordingly, T-cells derived from the human diabetic pancreas have been
demonstrated to express the gut-associated homing receptor β7-integrin (Hänninen et al.
1993). In addition, enterovirus and rotavirus infections have been associated with the
development of islet cell autoimmunity (Honeyman et al. 2000, Lönnrot et al. 2000). Both
types of viruses replicate in the gut and cause stimulation of the gut immune system.
Further evidence for a link between the gut immune system and type 1 diabetes comes
from experimental studies. Diet has been shown to modify the development of autoimmune
diabetes in biobreeding rats and nonobese diabetic (NOD) mice, which are animal models of
human T1D (Elliott et al. 1988, Scott et al. 1997, Scott et al. 2002). T-cells infiltrating the
pancreatic islets have been revealed to express the gut-associated homing receptor β7-
integrin, and antibodies that block this receptor or its endothelial ligand MAdCAM-1 inhibit
the development of autoimmune diabetes in NOD mice (Hänninen et al. 1996, Yang et al.
1997). Moreover, autoimmune diabetes has been transferred to the recipients by mesenterial
lymphocytes from young NOD mice, indicating that diabetogenic T-cells are present in the
gut immune system (Hänninen et al. 1998). Finally, feeding autoantigen induces the
development of autoreactive cytotoxic lymphocytes and the acceleration of autoimmune
diabetes (Blanas et al. 1996, Bellmann et al. 1998).
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However, it is not clear how an inflammation in the gut is associated with the process
that destroys β-cells in the pancreas, and only one study has investigated the immunologic
markers in the intestine of T1D patients so far. In this study an increased expression of HLA
class II antigens in the villous epithelium and an increased density of α4β7 expressing cells
were found in the lamina propria, reflecting a stage of inflammation even in structurally
normal small intestine of paediatric T1D patients when compared to controls (Savilahti et al.
1999). The role of these inflammatory changes in the intestinal mucosa of patients with T1D
is unclear and further evidence for the involvement of the gut immune system in T1D is
needed.
Th1/Th2 paradigm in T1D
Th1 cells have been suggested to be responsible for the initiation of the destruction of β-cells
in the pancreas. The paradigm of T1D as a Th1 cell mediated autoimmune disease is mainly
based on data from the animal models of the disease. In NOD mice and biobreeding rats the
islet infiltrating lymphocytes show IFN-γ expression, which is reduced when the
development of autoimmune diabetes is prevented by different interventions. IL-4 on the
other hand protected against insulitis and diabetes in young NOD mice (reviewed by
Rabinovitch and Suarez-Pinzon 2003). It is unclear if Th1 cells mediate β-cell destruction in
human T1D as well. Systemic deviation to Th1-type response has, however, been suggested
in human studies. Increased secretion of IFN-γ and TNF-α and low IL-4 production by
mitogen stimulated PBMCs has been reported in patients with T1D (Berman et al. 1996,
Kallmann et al. 1997).
5.3 Intestinal graft-versus-host disease
Allogeneic stem cell transplantation (SCT) is increasingly used to treat both malignant and
nonmalignant diseases, including acute and chronic leukaemias, lymphomas, aplastic
anaemia, and severe immunodeficiencies (Ferrara and Deeg 1991, Gratwohl et al. 2001).
Among the complications of SCT, graft-versus-host disease (GvHD) is one of the major
sources of morbidity and mortality (Ferrara and Deeg 1991). Approximately 10-50% of
patients with sibling (Klingebiel and Schlegel 1998, Saarinen-Pihkala et al. 2001) and over
60% with matched unrelated donor transplantation (Saarinen-Pihkala et al. 2001) have signs
of acute GvHD. The main target organs are the intestine, skin and liver. Symptoms of
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intestinal GvHD include diarrhoea, abdominal pain, nausea, and intestinal bleeding
(Klingebiel and Schlegel 1998, Iqbal et al. 2000).
The histology of acute intestinal GvHD progresses in experimental studies from
proliferation of epithelial cells to villous atrophy, with single crypt epithelial cell apoptosis
being the hallmark of GvHD (Mowat et al. 1988). Thus, the intestinal damage in murine
acute GvHD resembles the histological changes in human CD. The knowledge of the
histopathology in human intestinal acute GvHD is mostly based on studies on patients with a
severe disease or end-stage enteropathy (Snover et al. 1985, Mowat 1997, Iqbal et al. 2000).
Little is known about the histological picture during the early stages of human intestinal
GvHD. The histology has been prospectively documented in one clinical study, which only
evaluated rectal biopsies (Epstein et al. 1980). In this study the effect of cytoreductive
treatment on the rectal mucosa resolved within 3 weeks after SCT (Epstein et al. 1980).
Immunopathogenesis of GvHD
Donor T-cells are critical in the induction of acute GvHD, because depletion of T-cell from
the bone marrow graft prevents GvHD, but also increases the risk of leukaemic relapse
(Ferrara and Deeg 1991). The donor T-cells do not just encounter a foreign environment in
the host, but also one that has been altered by the underlying disease and the treatment; all
these promote activation of inflammatory cells as described below.
Most of the information on the pathophysiology of GvHD comes from animal studies.
Based on these studies immunopathogenesis of GvHD can be divided into three phases: 1)
host conditioning, 2) donor T-cell activation, and 3) inflammatory effectors (Hill and Ferrara
2000). In phase 1, host conditioning including chemotherapy with or without total body
irradiation leads to damage of host tissue. This leads to activation of host cells and secretion
of proinflammatory cytokines, such as TNF-α and IL-1, which increase the expression of
adhesion molecules, MHC antigens, and co-stimulatory molecules. Irradiation also induces
apoptosis of endothelial cells and damages epithelial cells in the gastrointestinal tract, which
allows microbial products to enter into the blood circulation. This further amplifies the GvHD
reaction (Mowat et al. 1988). In phase 2, host alloantigens activate donor T-cells that
differentiate into Th1- and/or Th2-type subsets. Th1 cytokines are preferentially produced in
acute GvHD and have been implicated to be responsible for GvHD by inducing cytotoxic
CD8+ T-cells and NK cell responses, as well as by activating monocytes to produce IL-1 and
TNF-α. Phase 3 of acute GvHD culminates in the host-cell destruction by cytolytic effects of
these activated cells and inflammatory mediators like IL-1, TNF-α and NO. The damage in
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the target organs includes apoptosis of epithelial cells and infiltration of immune cells (Hill
and Ferrara 2000).
In humans, the relevance of the data from experimental studies is, however, far from
clear. The early phases of the process are most likely clinically silent and the clinical
diagnosis is made at the late phase of the target-organ damage. Evidence from clinical studies
supports the concept that inflammatory cytokines, preferably TNF-α, and gastrointestinal
tract damage are important mediators of clinical GvHD as well. Increased serum levels of
TNF-α preceded severe acute GvHD with a latency of 25-54 days in adult SCT patients
(Holler et al. 1990), and application of a monoclonal antibody neutralising TNF-α
(infliximab) postponed the onset of acute GvHD after SCT in a clinical trial (Holler et al.
1995). However, the expression of cytokines in acute intestinal GvHD at the tissue level has
not been characterised in humans. Clearly, studies on human tissues are needed to verify the
proposed immunopathogenesis of GvHD.
5.4 Food allergy
The prevalence of food allergy is estimated as high as 8% in children less than 3 years of age
in the Western world. The prevalence has increased during the last three decades. The
majority of young children have a classic type I, IgE-mediated immediate immune response.
In delayed-type food allergy, intestinal symptoms appear over several hours or even days
after exposure to the allergen, and the reaction is non-IgE mediated (reviewed in Helm and
Burks 2000). Immune mechanisms causing delayed food allergy are not well defined, but at
least in the chronic entropathy T-cells play a role. Food allergy is most commonly caused by
proteins of cow's milk, egg, peanuts, fish, and wheat (Sampson 1999).
Enteropathy associated with allergy to cow's milk, causing chronic diarrhoea and
malabsorption was described 40 years ago (reviewed by Savilahti 2000). This form of food
hypersensitivity resembles clinically and pathologically CD, except that there is no genetic
determinant known so far. It seems to develop because of the immaturity of mucosal immune
system on early exposure to cow's milk and ameliorates as the patient's immune system
develops. The syndrome is cured by elimination of cow's milk from the diet.
Th1/Th2 paradigm in food allergy
In early infancy many of the mechanisms involved in the development of oral tolerance are
impaired. The permeability of the gut to macromolecules is increased (Kuitunen et al. 1994),
REVIEW OF THE LITERATURE
___________________________________________________________________________
38
enabling antigens to pass the mucosal barrier and impairing the normal antigen handling
(Sanderson and Walker 1993). The immune system is immature, with few IgA-producing
cells and a skewing of the Th1/Th2 ratio towards a Th2 dominance (reviewed by Holt and
Jones 2000). The Th2 dominance continue in infants during the first year of life, whereafter a
Th1 dominance develops. However, several studies have shown that children with atopy or
cow's milk allergy continues to show a Th2 skewing with a high production of IL-4 and IL-5,
and low production of IFN-γ by the peripheral blood leukocytes (Hill et al. 1993,
Suomalainen et al. 1993, André et al. 1996, Prescott et al. 1998). IL-4 is the main cytokine
that promotes IgE production (Del Prete et al. 1988), suggesting that aberrant cytokine
profiles play a central role in the pathogenesis of IgE-mediated food allergy.
Although cytokine imbalance has also been proposed to be important in the
pathogenesis of delayed-type food allergy (Hill et al. 1993, Sütas et al. 1997), only one study
had addressed this in the gut prior to our study. Hauer et al. showed an elevation in the
number of cells secreting IFN-γ and, to a lesser extent, IL-4, isolated from duodenal biopsies
of 14 infants with cow's milk sensitive enteropathy by enzyme-linked immunoabsorbant spot
technique (Hauer et al. 1997). Cells secreting IFN-γ were ten times more abundant than cells
secreting IL-4, indicating a Th1 dominance. However, by RT-PCR they found higher
expression of IL-4 and IL-10 mRNA than of IFN-γ mRNA (Hauer et al. 1997).
Symptoms and diagnosis of food allergy
The evidence of IgE mediation in acute food allergy is well established. It most commonly
manifests as erythematous and urticarial skin symptoms, but acute gastrointestinal symptoms
often associate these or may occur alone. The gastrointestinal symptoms of delayed food
allergy are chronic diarrhoea, more rarely vomiting or constipation, and the associating skin
symptom is chronic eczema. Food allergy may also induce respiratory symptoms such as
allergic rhinitis, wheezing or cough.
The diagnosis of food allergy is based on the disappearance of symptoms when on an
elimination diet for at least 2 weeks, followed by their reappearance during a challenge test
and clinical response to a renewed elimination diet (diagnostic criteria by ESPGHAN
(ESPGHAN 1992). The food challenge should be double-blind placebo-controlled in order to
not cause any bias. No clinical symptoms or laboratory test can predict the challenge
outcome.
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6. MICROSCOPICAL FINDINGS IN IMMUNOLOGIC INFLAMMA-
TIONS
6.1 Morphology of the small intestine
Histopathology
The mucosal atrophy in coeliac disease develops through various stages of severity, which
according to the classification by Marsh can be graded from type 1 to type 3 lesions (Marsh
1992). In the infiltrative (type 1) lesion, the mucosal architecture is still normal, but there is
an increased number of intraepithelial lymphocytes, especially γδTCR bearing IELs. In the
hyperplastic stage (type 2), the villi are still of normal height, but the crypts are elongated due
to increased generation of immature epithelial cells in the crypts in order to compensate for
the increased epithelial cell loss on the villi. This stage progresses to the destructive (type 3)
lesions, which show the typical flat mucosa with crypt hyperplasia. The same histopathology
as for type 1-type 3 has also been documented in graft-versus-host disease (Mowat 1997),
and in cow's milk (Walker-Smith et al. 1978, McCalla et al. 1980, Kuitunen et al. 1982) or
soy allergy (Perkkiö et al. 1981). The absence of ulcerations and transmural thickening
distinguishes the cellular infiltrate in these enteropathies from that in Crohn's disease.
Intraepithelial lymphocytes
In coeliac disease the density of CD3+ IELs is increased (Marsh 1992, Järvinen et al. 2003).
The increase is even more pronounced in the population of intraepithelial cells bearing the
γδTCR, which constitutes up to one third of the IELs in coeliac lesions (Savilahti et al. 1990).
In normal small intestine, there are 10-20 IELs per 100 epithelial cells (Ferguson and Murray
1971), which correlates with a density of 10-50 IELs per mm of surface epithelium (Savilahti
et al. 1990). The increased density of γδTCR+ IELs is considered the hallmark of CD
(Halstensen et al. 1989, Spencer et al. 1989). The density of αβTCR+ cells is dependent on
gluten, while the density of γδTCR+ cells has been reported to remain increased even during a
gluten-free diet (Savilahti et al. 1990, Savilahti et al. 1992, Savilahti et al. 1997, Järvinen et
al. 2003). However, the frequency of γδTCR+ IELs has also been reported to decrease on
gluten-free diet (Spencer et al. 1989, Iltanen et al. 1999).
The increased density of IELs is not specific for CD. IELs are also increased in food
allergy enteropathies in humans (Perkkiö et al. 1981, Kuitunen et al. 1982, Kokkonen et al.
2000) and in murine GvHD (Mowat et al. 1988). In patients with severe food allergy
enteropathy studies have also shown a moderately increased density of γδTCR+ intraepithelial
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lymphocytes (Spencer et al. 1991, Kokkonen et al. 2000). An increase of γδTCR+ IELs was
also documented in school-aged children with slow developing mild gastrointestinal
symptoms upon cow's milk challenge (Kokkonen et al. 2001a).
Lamina propria infiltration
The volume of the lamina propria is enlarged in the jejunal specimens of patients with
untreated CD (Marsh 1992). The mature lesions of CD contain a mixture of T- and B-cells
and macrophages. There is a marked accumulation of IgA-, IgM and IgG-producing plasma
cells (Savilahti 1972). The absolute number of T-cells is increased in coeliac lamina propria
(Beckett et al. 1996, Arató et al. 1998), with twice as many T-cells bearing the γδTCR than
observed in normal mucosa (Savilahti et al. 1990). Most of the T-cells are still αβTCR+
(Halstensen et al. 1989, Spencer et al. 1991), and there is no change in the CD4/CD8 ratio. A
larger proportion of T-cells, especially in the CD4+ cell population, show activation markers
(CD45R0, various integrins and CD25). Nevertheless, few bear markers associated with cell
proliferation (reviewed by MacDonald and Spencer 1990).
In food allergy, the numbers of lymphocytes, plasma cells and eosinophils are
increased in the lamina propria. Early studies on immunoglobulins in the intestines of patients
with this syndrome showed a strong infiltration of IgA and IgM containing cells at the time of
clinical reaction either to cow's milk or soy (reviewed by Savilahti 2000). CD4+ T-cells
predominate in the lamina propria, and many CD4+ cells are also HLA-DR+, suggesting that
they are activated. The number of these cells diminished during a cow's milk elimination diet
(Nagata et al. 1995).
6.2 Production of cytokines
Since the discovery of cytokines they have been the focus of extensive research in various
inflammatory conditions of the intestine. Still, there is no comprehensive data on cytokine
expression in the normal human small intestine. Probably the best indication of the cytokine
secretion by normal lamina propria T-cells so far comes from three studies where freshly
isolated human lamina propria T-cells were shown to spontaneously secrete excessive IFN-
γ, followed by weaker secretion of IL-4, IL-5, and IL-10 (Hauer et al. 1997, Carol et al. 1998,
Hauer et al. 1998). Freshly isolated PP T-cells also contained more IFN-γ than IL-4 secreting
cells, but the expression of IL-4 and IL-10 mRNA was higher than the expression of IFN-γ
mRNA (Hauer et al. 1998). Lamina propria cells, but not epithelial cells, secrete IL-
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1 (Youngman et al. 1993), whereas freshly isolated IEL secrete IFN-γ (Lundqvist et al. 1996,
Carol et al. 1998). Thus, lamina propria T-cells secrete spontaneously far more cytokines than
peripheral blood T-cells.
An early study on cytokine production by lamina propria lymphocytes in coeliac
disease did not detect increased IFN-γ (al-Dawoud et al. 1992), whereas more recent studies
all suggest a Th1 dominated response. Studies with intact jejunal biopsies from CD patients
have shown increased expression of IFN-γ mRNA (Kontakou et al. 1994, Lahat et al. 1999),
and increased IFN-γ mRNA production by gluten-specific intestinal T-cell clones (Nilsen et
al. 1995, Troncone et al. 1998). After a wheat peptide challenge an increase in the number of
cells expressing mRNA for IFN-γ and IL-6 was observed in all four investigated patients,
whereas mRNA for TNF-α and IL-2 was increased in two out of four patients (Kontakou et
al. 1995b). In addition, increased IFN-γ mRNA is seen after ex vivo gliadin challenge of
small intestinal biopsies of CD patients (Nilsen et al. 1998, Troncone et al. 1998).
Furthermore, anti-IFN-γ treatment in small intestinal organ cultures of CD patients in vitro
inhibits the histological changes induced by gliadin sensitive T-cells (Przemioslo et al. 1995).
Some gluten specific T-cell clones from coeliac intestinal lesions secrete TNF-α, IL-4,
IL-5, IL-6, IL-10, and TGF-β, although much less than IFN-γ (Nilsen et al. 1995, Troncone et
al. 1998). Studies with intact biopsies have also reported a somewhat higher frequency of
TNF-α mRNA positive specimens in active CD (Lahat et al. 1999), increased frequencies of
TNF-α positive cells (Przemioslo et al. 1994, Kontakou et al. 1995a, Kontakou et al. 1995b),
and sometimes increased mRNA levels after ex vivo challenge (Nilsen et al. 1998).
Additionally, other macrophage-derived cytokines, such as IL-6 have been found in biopsy
specimens from CD patients (Przemioslo et al. 1994, Kontakou et al. 1995a, Kontakou et al.
1995b).
Studies on IL-4 and IL-10 are contradictory. Increased mRNA production in CD biopsies was
reported by one group for IL-10 but not for IL-4 (Lahat et al. 1999), while Nilsen et al. found
increased IL-10 mRNA and protein, but no IL-4 (Nilsen et al. 1998), and Beckett et al. found
no changes in either IL-4 or IL-10 by immunohistochemistry and in situ hybridisation
(Beckett et al. 1996).
6.3 Expression of HLA class II antigens
MHC class II molecules are present in the epithelium of normal small intestine. Staining with
antibodies against HLA-DR antigens has shown that positive expression in the normal small
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intestine is restricted to the apical cytoplasm of the epithelial cells and that the intensity
decreases from the top of the villous, leaving the crypts negative (Scott et al. 1980, Arnaud-
Battandier et al. 1986, Ciclitira et al. 1986). In addition, capillary walls and mononuclear
cells in the lamina propria stain positively (Scott et al. 1980). Staining with HLA-DP
antibodies show a similar pattern, but the epithelial cells show a weaker staining than
mononuclear cells (Marley et al. 1987, Mayer et al. 1991).
The expression of HLA-DR and –DP is increased in a number of diseases. In CD, the
whole cytoplasm, as well as the basal surface of epithelial cells in the surface and crypt
epithelium stain positively with HLA-DR (Arnaud-Battandier et al. 1986, Ciclitira et al.
1986, Kelly et al. 1988). HLA-DP stainings have shown an increased positive staining in both
surface and crypt epithelium compared with control subjects (Marley et al. 1987, Kelly et al.
1988). The numbers of HLA-DR and -DP positive mononuclear cells in the lamina propria
are also increased (Kelly et al. 1988). When on a gluten-free diet the staining of MHC class II
molecules does not differ from that seen in controls (Arnaud-Battandier et al. 1986, Ciclitira
et al. 1986, Arato et al. 1987). Increased staining has also been documented in first-degree
relatives of CD patients (Holm et al. 1994). In addition to CD, increased expression of HLA-
DR and –DP has been documented in the epithelium in Crohn's disease (Mayer et al. 1991),
autoimmune enteropathy (Hill et al. 1991), in rat GvHD (Mason et al. 1981), and in jejunal
biopsies of patients with T1D (Savilahti et al. 1999).
Despite numerous studies, positive staining for HLA-DQ in the normal (Marley et al.
1987, Kelly et al. 1988) or diseased small intestinal epithelium has not been shown (Kelly et
al. 1988, Mayer et al. 1991, Schweizer et al. 1991, Holm et al. 1994, Klemola et al. 1995,
Savilahti et al. 1999). The expression of HLA-DQ antigens has been confined solely to cells
within the lamina propria, without any difference between control patients and patients with
inflammatory diseases. The reason for absent HLA-DQ expression is unknown. Alternatives,
like a too low sensitivity of the methods and antibodies used, as well as a posttranscriptional
defect in HLA-DQ gene expression, have been suggested (Kelly et al. 1988, Mayer et al.
1991).
6.4 Proliferation and apoptosis of epithelial cells
The epithelial cells are produced in the crypts of Lieberkühn from progenitor cells and
mature as they migrate up the crypt-villous axis. At the end of their 3-4 day-long life-span
(Podolsky 1993), they undergo apoptosis and are shed into the gut lumen from the tip of the
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villous (Ruemmele et al. 2002). Approximately 5-15% of the epithelial cells in the crypts are
proliferating in the normal small intestine, as shown by immunohistochemical stainings with
the antibody Ki-67 (Moss et al. 1996, Maiuri et al. 2001). Ki-67 is an antibody reacting with
a protein in the nucleus of cells undergoing proliferation (Gerdes et al. 1983). In
inflammatory states, the number of cells undergoing mitosis in the crypts is increased to
compensate for the increased loss of surface epithelial cells. In CD, the epithelial cell renewal
rate is increased as the result of both an increased mitosis rate and larger crypt cell
compartment (Wright et al. 1973). In food allergy, an increased mitotic activity in the crypts,
though of a moderate degree, has been documented as well (reviewed in Savilahti 2000).
Apoptosis is a programmed, noninflammatory form of cell death leading to the
clearance of injured cells without disruption of tissue structure or function. The process leads
to shrinkage and fragmentation of the cell and its nucleus and degradation of chromosomal
DNA. Apoptosis is induced by diverse factors such as Fas-ligand, TNF, irradiation and
genotoxic agents, such as anti-cancer drugs. In disease, apoptosis is an important mechanism
for promoting resolution of inflammation and protecting against connective tissue formation
by eliminating infiltrating leukocytes and proliferating cells (reviewed by Reed 2000).
Staining of apoptotic cells by in situ DNA 3'-end labelling (ISEL) (Gavrieli et al. 1992)
shows that approximately 1-2% of the surface epithelial cells and 2-3% of crypt epithelial
cells are undergoing apoptosis in the normal small intestine (Maiuri et al. 1997, Ciccocioppo
et al. 2001, Maiuri et al. 2001). In CD the proportion of crypt and surface epithelial cells
undergoing apoptosis is as high as 30-40%, while the percentage is normalised during gluten-
free diet (Moss et al. 1996, Ciccocioppo et al. 2001, Maiuri et al. 2001).
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AIMS OF THE STUDY
The objective of this study was to evaluate the expression patterns of cytokines and
immunologic markers in inflammatory disorders of the small intestine in vivo.
Immunologically mediated enteropathies consist of a group of different diseases that
are characterised by varying degree of villous destruction in the small intestine.
Characteristics of these diseases are excessive T-cell activation and production of
proinflammatory cytokines, such as IFN-γ and TNF-α. The increased production of
proinflammatory cytokines has been suggested to be one of the factors causing villous
atrophy. However, the knowledge of intestinal expression of cytokines is mainly based on
studies on overt CD. Knowledge of the intestinal expression of cytokines in GvHD was, prior
to this study, based only on experimental studies. Furthermore, the expression of cytokines
has not been determined in the potential form of CD, nor in other early and mild forms of
these intestinal inflammations, such as mild forms of food allergy enteropathy. Since the
mucosa is still intact in these disorders, it can be postulated that studying cytokines at this
stage could be more informative on the role of cytokines in mediating chronical inflammation
and villous atrophy.
Immunologic inflammation in the intestine may also play a central role in the
development of autoimmune diseases. Based on experimental studies, the gut immune system
seems to play a role in the pathogenesis of type 1 diabetes. In addition, immunologic changes
have been observed in the small intestine of patients with T1D, which implies a role for the
gut immune system in human T1D as well.
Therefore, the specific aims of this study were:
1) To characterise the possible T-cell activation and the cytokine expression in the small
intestine of patients with potential CD
2) to analyse the activation of the immune system in the small intestine of patients with T1D
3) to characterise cytokine profiles and T-cell markers in the intestinal mucosa of patients
undergoing SCT in order to identify changes associated with human GvHD
4) to characterise the expression of cytokines and adhesion molecules in the small intestine
of patients with food allergy
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PATIENTS AND METHODS
1. Patients with potential coeliac disease (I)
Duodenal biopsies were obtained from five paediatric family members of CD patients and
from four adult family members of DH patients. In addition, one sample from a paediatric
patient with overt CD developing 11 months later was included in this potential CD study
group. Seven paediatric patients and one adult patient with untreated CD served as a positive
reference group. The diagnosis of CD was set according to the ESPGHAN criteria (Walker-
Smith et al. 1990). As a negative reference group eight paediatric control patients undergoing
upper gastroscopy because of growth retardation, gastrointestinal symptoms, positive
antigliadin antibodies or any combinations of these were also included in the study. The
control patients had no history of CD or DH in the family. They were not on medication, and
did not have any chronic diseases. The morphology of the jejunum was normal, and the
endomysium (EMA) and tissue transglutaminase (tTGA) antibodies were negative in all
control children. The clinical data are summarised in Table 3.
Table 3. Characteristics of patients in study I
Normal controls
Paediatric
potential CD
patients
Adult potential
CD patients CD patients
n 8 6 4 8 (including 1 adult)
F/M 4/4 3/3 3/1 5/3
Age in years,
median (range) 6.9 (2.6-13.7) 6.1 (3.7-14.5) 53.5 (38-75)
1 adult, 31 years
7 paed., 6.6 (2.5-17.3)
Pos EMA1 0/4 (4 NT) 4/6 0/4 8/8
Pos tTGA2 0/3 (5 NT) 3/6 (1 NT) 0/0 (4 NT) 6/8 (1 NT)
Pos Gliad-IgA3 1/8 1/6 0/4 3/8
Pos Gliad-IgG 3 7/8 3/6 0/4 3/8
Morphology Normal 8/8 Normal 6/6 Normal 4/4 1 PVA, 7 SVA
1 Class IgA endomysium antibodies, upper normal limit 1:5 (Kolho and Savilahti 1997), 2 Class IgA
tissue transglutaminase antibodies, normal limit 8% (Stern 2000), 3 Class IgA and IgG gliadin
antibodies, upper normal limit 20% for both (Kolho and Savilahti 1997). NT, not tested; PVA, partial
villous atrophy; SVA, subtotal villous atrophy.
2. Patients with type 1 diabetes (II)
In study II 32 small intestinal biopsy specimens were obtained from 31 paediatric patients
with type 1 diabetes. The patients were scheduled for biopsy because of positive antibodies
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associated with coeliac disease in the annual CD screening tests, or because of some
gastrointestinal complaints or growth retardation. The patients were divided into three
groups; T1D patients with normal villous structure and low titre of CD autoantibodies, T1D
patients with normal villous structure and positive EMA or tTGA, referred to as potential CD,
and T1D patients with untreated CD. Two of the patients with normal mucosa had a low titre
of EMA and negative tTGA antibody tests. These patients were included in the group with
negative CD autoantibody tests. The diagnosis of CD was set according to the criteria by
ESPGHAN (Walker-Smith et al. 1990).
Additionally, twelve age-matched control paediatric patients were included in the
study, seven of which were the same as those in study I and the other five control patients
were new for this study. These twelve control patients also served as controls in study III.
The exclusion criteria for the controls were the same as in study I. The clinical data of the
patients are summarised in Table 4.
Table 4. Characteristics of patients in study II
Normal
controls
T1D patients
with normal
mucosa
T1D patients
with potential
CD
T1D patients
with CD
n 12 16 8 8
F/M 8/4 8/8 3/5 5/3
Age in years, median
(range) 6.7 (1.6-13.7) 9.8 (2.9-18.2) 9.7 (6.0-13.2) 8.7 (3.9-15.8)
Age at onset of T1D;
years, median (range) 3.3 (1.2-12.5) 8.0 (2.2-11.8) 5.8 (1.7-9.3)
Duration of T1D at biopsy;
years, median (range) 6.6 (0.3-13) 1.3 (0.1-4.4) 2.7 (0.3-6.5)
Pos EMA1 0/8 (4 NT) 2/13 (3 NT) 8/8 7/7 (1 NT) 5
Pos tTGA2 0/7 (5 NT) 0/13 (3 NT) 6/7 (1 NT) 5/5 (3 NT)
Pos Gliad-IgA3 3/12 7/16 1/8 6/8
Pos Gliad-IgG 3 10/12 9/16 3/8 4/8
Morphology Normal 12/12 Normal 16/16 Normal 7/8 4 3 PVA, 5 SVA
HLA-DQ2 NT 3/15 (1 NT) 6/8 4/8
HLA-DQ8 NT 2/15 (1 NT) 2/8 2/8
1 Class IgA endomysium antibodies, upper normal limit 1:5, <1:50 weak positivity (Kolho and
Savilahti 1997), 2 Class IgA tissue transglutaminase antibodies, normal limit 8% (Stern 2000), 3 Class
IgA and IgG gliadin antibodies, upper normal limit 20% for both (Kolho and Savilahti 1997), 4 Slight
changes in one biopsy, villous height was still normal, 5 The patient not tested had positive IgA
reticulin antibodies. NT, not tested; PVA, partial villous atrophy; SVA, subtotal villous atrophy.
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3. Patients undergoing stem cell transplantation (III)
Duodenal biopsies from patients undergoing allogeneic stem cell transplantation, who were
enrolled in a sodium chromoglycate prophylaxis study against gastrointestinal graft-versus-
host disease, were investigated in this study. The prospective study was run at the Hospital
for Children and Adolescents, University of Helsinki, Finland, between November 1995 and
October 1998. Initially, 44 patients over 1 year of age were invited prior to allogeneic SCT,
and 20 were willing to take part in the study. All patients received cyclosporin from day -1 on
and methotrexate on days 1, 3, 6 and 11 as conventional GvHD prophylaxis. Signs and
symptoms of GvHD were recorded and graded according to conventional criteria (Thomas et
al. 1975). Sodium chromoglycate did not alter the clinical, histological or immunological
picture of the patients. Therefore, we combined the data from both the sodium chromoglycate
and placebo groups.
Gastroscopy was prospectively scheduled at 6-7 and 12 weeks after SCT. The
endoscopy at 6 weeks was performed to 17 study patients, and the follow-up endoscopy at 12
weeks was performed to 12 patients. Of these, 12 and 8 duodenal biopsies, respectively, were
available for the studies presented here. In addition, three SCT patients with grade III-IV
clinical and histologically proven gastrointestinal GvHD, not taking part in the
chromoglycate study, were included as clinical GvHD patients. The biopsies from these
clinical GvHD control patients were obtained at the time of intestinal symptoms at 3, 6 and
11 weeks, and the follow-up biopsies at 10-16 weeks after SCT, respectively. The
characteristics of only the patients whose duodenal biopsies were investigated are presented
in Table 5. The same 12 patients included and presented in study II served as normal
paediatric controls.
PATIENTS AND METHODS
___________________________________________________________________________
48
Table 5. Characteristics of SCT patients in study III
SCT study
patients
Clinical GvHD
patients
n 12 3
F/M 4/8 0/3
Age at SCT in years, median
(range) 7.1 (1.8-13.8) 6.4 (2.8-6.6)
Time since SCT at biopsy in
days, median (range) 48 (40-96) 43 (21-78)
Time since SCT at the second
biopsy in days, median (range) 111 (71-231) 99 (71-112)
Donor; URD / sibling 7 / 5 2 / 1
TBI 8/10/12/14 Gy(1/9/1/1 patients)
12 Gy
(3 patients)
Clinical intestinal GvHD
- at 6 weeks (grI-IV) 2 grI, 2 grIV 3 grIV
- at 3 months 1 grIII 3 grIV
Small intestinal histology GvHD
- at 6 weeks (grI-IV) - 1 grII, 2 grIII
- at 3 months 1 gr III 1 grII, 2 grIII
Diagnosis
- ALL / AML 6 / 1 3 / 0
- Other malignancy 2 -
- Non-malignant disease 3 -
Chromoglycate / placebo 6 / 6 -
Abbreviations: ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia;
gr, grade; TBI, total body irradiation; URD, unrelated registered donor.
4. Patients with food allergy (IV)
Specimens from the bulb of the duodenum were taken from 14 paediatric patients with food
allergy. Seven were on a normal diet and seven were on a restricted diet, but still had some
clinical symptoms as an indication for gastroscopy, at the Oulu University Hospital.
Diagnosis of food allergy was based on an open 6-week elimination/challenge test with the
triggering food protein according to the diagnostic criteria by ESPGHAN (ESPGHAN 1992).
Before the challenge, the patients were on a food elimination diet involving the suspected
food for at least 2 weeks. Open oral challenges were performed with an increasing daily dose,
starting from 1 ml of cow's milk or 1 g of cereals (gluten-containing cereals and oats,
separately). Each period was continued for 2 weeks if symptoms did not manifest earlier.
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Abdominal pain, diarrhoea or loose mucous stools, or exacerbation of dermatitis were each
considered a positive result. In all cases symptoms appeared at earliest after 24 hours from
the beginning of the challenge.
The study also included five paediatric control patients and five paediatric patients with
untreated CD. The controls were studied for diagnostic purposes, they all had normal
endoscopic and histologic results and no history of allergy. Furthermore, CD was excluded
by serological testing and lactose intolerance was ruled out. The criteria for CD diagnosis
was the same as in study I. The characteristics of the patients are summarised in Table 6.
Table 6. Characteristics of patients in study IV
Normal
controls
FA patients on
normal diet
FA patients with
restricted diet
CD patients
n 5 7 7 5
F/M 0/5 4/3 5/2 2/3
Age in years, median (range) 12.9 (4.5-16.1) 6.8 (2.0-12.9) 11.3 (0.9-14.2) 6.4 (2.5-15.2)
Allergen: milk 6 5
Allergen: cereals 3 3
Duration of diet; years,
median (range) 3 (1-13)
Pos EMA1 0/5 0/7 0/7 5/5
Morphology, LNH Normal 5/5 LNH 6/7 LNH 7/7 5 SVA
Specific IgE >0.7 IU/l - 2/5 (2 NT) 2/2 (5 NT) -
Positive skin prick test - - 1/1 (6 NT) -
1 Class IgA endomysium antibodies, upper normal limit 1:5 (Kolho and Savilahti 1997). FA, food
allergy; LNH, lymphonodular hyperplasia; NT, not tested; SVA, subtotal villous atrophy.
5. Samples (I-IV)
A Watson capsule biopsy device or a gastroscope was used to take a specimen from the distal
duodenum or the proximal jejunum in study I-III, and from the bulb of the duodenum in
study IV. Endoscopies were performed under general anaesthesia.
The specimens were embedded in optimal cutting temperature (OCT) compound (Miles
Laboratories), snap frozen in liquid nitrogen, and stored at -70°C. Frozen tissue samples were
cut into 8-µm sections for immunohistochemistry and ISEL analysis, and into 8- or 10-µm
sections for in situ hybridisation. The sections were coded and evaluated without knowledge
of the specimen identity.
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6. Ethical considerations (I-IV)
Specimens from paediatric patients in study I and II were taken for diagnostic purposes at the
Hospital for Children and Adolescents, Helsinki University Central Hospital. The St. Mary's
Hospital ethics committee approved biopsies taken from the adult siblings of patients with
DH in study II. The specimens from SCT patients in study III were taken because of the
sodium chromoglycate prophylaxis study, and the study protocol was approved by the
Institutional Review Board. Oral witnessed informed consent was obtained from the parents
and age-appropriate patients. Use of the biopsy specimens in study I-III was approved by the
ethics committee of the Hospital for Children and Adolescents, Helsinki University Central
Hospital. Gastroscopy of the patients in study IV were performed for diagnostic purposes at
the Department of Paediatrics, University of Oulu. For an additional biopsy sample, a written
parental consent was obtained from the parents of all children. The protocol was approved by
the ethics committee at Oulu University Hospital.
7. Immunohistochemistry (I-IV)
Immunohistochemistry was performed using a commercially available avidin-biotin
immunoperoxidase system (Vectastain Elite ABC kit) according to the manufacturer's
instructions. Cryostat sections were fixed in acetone for 10 min at +4°C, washed with PBS,
and blocked for 30 minutes at room temperature with normal horse serum. Following
blocking, the sections were incubated for one hour at room temperature with the primary
antibodies described in Table 7. The slides were then treated with 0.5% hydrogen peroxide in
methanol for 20 minutes at room temperature to block endogenous peroxidase activity.
Subsequently, secondary biotinylated antibody was applied, followed by avidin-biotin-
peroxidase complex. 3-amino-9-ethylcarbazole (Sigma) was used as chromogen, and Harris
haematoxylin was used for counterstaining.
Permeabilisation was performed prior to immunostaining of cytokines by incubating
the slides in 0.1% PBS-Tween20 for 10 minutes in room temperature. The cytokine
antibodies were diluted in 1% normal horse serum in 0.1% PBS-Tween20 and the slides
incubated with the mAbs for one hour at +37°C in a humidified chamber. As controls for
specific staining, one additional mAb for IL-4 (clone 82.2, Mabtech) and IFN-γ (clone7-B6-
1, Mabtech) were used, and similar staining patterns obtained.
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Nonimmune mouse IgG1 (DAKO) was used as a negative primary antibody control
and incubation with 1% normal horse serum on additional sections as the negative control for
the reagents in the avidin-biotin immunoperoxidase system.
Table 7. Monoclonal mouse-antihuman antibodies used in immunohistochemistry
Antibody Dilution Company; clone Study
CD3 1:200 (1:400 IV) Becton-Dickinson I-IV
γδTCR 1:200 (1:400 IV) Endogen; clone 6A6.E9 I-IV
αβTCR 1:40 (1:50 I, 1:100 IV) Endogen; clone 8A3 I-IV
CD4 1.20 Coulter Immunology IV
CD8 1:400 DAKO; clone DK25 IV
ICAM-1 1:1500 (I,II) 1:2000 (III,IV) Endogen; clone VF27 I-IV
HLA-DR 1:500 (II,III) 1:2000 (I,IV) Becton-Dickinson I-IV
HLA-DP 1:40 Becton-Dickinson I-IV
Ki-67 1:100 DAKO I-IV
CD25 (IL-2 receptor) 1:10 DAKO; clone ACT-1 IV
CD11a (LFA-1) 1:100 Immunotech; clone 25.3.1 IV
ACT-1 (α4β7-integrin) 1:200 Leukosite IV
IL-1α 1:50 (1:100 I) Biosource International; clone 20B8 I-III
IL-2 1:50 Biosource International; clone 7A3 I-III
IL-4 1:50 Mabtech; clone 12.1* I-IV
IFN-γ 1:50 Mabtech; clone 1-D1K I-IV
TNF-α 1:50 Biosource International;clone 68B6A3 I-III
Nonimmune mouse
IgG
1:100 DAKO I-IV
* In study IV, IL-4 clone 82.4 was used at a dilution of 1:75
Microscopic evaluation
The numbers of positively stained mononuclear cells in the biopsies were counted
systematically under a light microscope through a calibrated eyepiece graticule at x1000
magnification. In the same specimen, the positively cells in at least 30 fields both in the
surface epithelium and the lamina propria were counted. The results were expressed as the
mean number of positive staining cells/mm of epithelium and as cells/mm2 in the lamina
propria, respectively. Proliferating cells were stained with Ki-67, and positively staining crypt
epithelial cells were calculated as percentages of all the crypt cells, with at least 200 cells
counted in each specimen.
Epithelial staining with HLA-DR and HLA-DP antibodies was graded in studies I-III
from 2 to 6 according to their intensity and cellular distribution (1=positive staining only on
the apical surface of the epithelial cell, 2=in addition, positive staining of the basal surface of
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epithelial cell, 3=in addition, positive staining throughout the cytoplasm of the epithelial
cell), and area of staining (1=only the tip of the villous positive, 2=the whole villous, no
positive crypts, 3=also positive staining in the crypts) (Klemola et al. 1995). The positive
staining for ICAM-1 in the lamina propria was estimated and graded from 1 to 3 according to
intensity of staining (1=weak positivity, 2=moderate positivity, 3=intense positivity). In study
IV proportions of positive epithelial cell staining with HLA-DR and HLA-DP, and positive
lamina propria cell staining with ICAM-1 were measured by Weibel's point counting
technique, using an integration ocular with a grid with 100 points. At least 1500 points falling
on epithelial cells (HLA-DR and HLA-DP) or lamina propria cells (ICAM-1) were counted
in each specimen. Each point was documented as positive or negative and the percentage of
positive points calculated.
8. Radioactive in situ hybridisation (I-IV)
Serial cryostat sections were processed for in situ hybridisation and immunohistochemistry
for IL-4 and IFN-γ. Cryostat sections were fixed in 4% paraformaldehyde in PBS, and
subjected to in situ hybridisation for human IL-4 and IFN-γ riboprobes obtained from the
cDNAs described below. Tissue sections were hybridised with 1.2 x 106 cpm of [33P]-labelled
(1000-3000 Ci/mmol; Amersham) antisense or sense riboprobes overnight at +60°C in a total
volume of 80 µl following the in situ protocol described in detail previously (Wilkinson
1992). The sections were treated with RNAse A to remove unhybridised probes, before
applying photographic emulsion. The slides were developed after 1 and 2 weeks of
autoradiography, and counterstained with Harris haematoxylin.
Human IL-4 and IFN-γ were used for preparing the riboprobes. Briefly, a 462-bp
human IL-4 cDNA and a 501-bp human IFN-γ cDNA were synthesised by PCR, enclosing
the whole coding region for both cytokines, and additionally the signal peptide for IFN-
γ (Sareneva et al. 1994). The PCR products were cloned into pGEM®-3ZF vectors (Promega)
and the sequences of the cloned PCR products were verified with an ABI PRISM 377 DNA
sequencer (Perkin-Elmer, Applied Biosystems). The lengths of the [33P]-labelled riboprobes,
both antisense and sense, were checked by SDS PAGE analysis.
Microscopic evaluation
Positive mRNA expression for IL-4 and IFN-γ was in study I and IV counted in two
representative areas in the lamina propria, as well as in the background staining adjacent to
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the tissue at x400 magnification. The relative intensity of positive mRNA signal was
determined by division of the positivity in the tissue by the positivity of the background. In
study II and III, positively staining cells were counted through a calibrated graticule at x400
magnification and expressed as the mean number of positive cells/area of epithelium or
lamina propria. A cell was considered positive if expressing 7 or more positive cytoplasmic
grains, which always corresponded to more than twice the background level. For the specific
probes, a minimum of two sections were prepared for each patient investigated.
9. Taqman real time PCR (II)
The part of the mucosal specimens from T1D patients still left after immunohistochemistry
and in situ hybridisation was used for RT-PCR. Total RNA was isolated from the mucosal
samples with GenEluteTM Mammalian total RNA kit (Sigma) following the manufacturer's
instructions. Reverse transcription of RNA to cDNA was performed with TaqMan® Reverse
Transcription Reagents (Applied Biosystems) in a reaction volume of 75 µl following the
manufacturer's instructions. The reaction mixture contained 10 ng/µl template RNA, 5.5 mM
MgCl2, 500 µM of each dNTP, 0.4 IU/µl RNase Inhibitor, and 2.5 µM Random Hexamers as
primers. The solution was treated with 2 IU of DNAse at 37°C for 30 minutes prior to 5
minutes inactivation at 75°C. After addition of 25 IU of MultiScribe® Reverse Transcriptase,
the RT reaction was carried out at 25°C for 10 min, 48°C for 30 min and 95°C for 5 min. The
samples were stored at -20°C until used.
Real-time quantitative PCR was performed using specific TaqMan® PDAR (Pre-
Developed assay reagents) primers/probes and the ABI-Prism 7700 Sequence Detection
System (Applied Biosystems) as described earlier (Heid et al. 1996). TaqMan®
primers/probes for cytokines IL-2 (PN 4309882P), IL-4 (PN 4309883P), IFN-γ (PN
4309890P) and TNF-α (PN 4309891P), and for chemokine receptors CCR-4 (PN 4312819P)
and CCR-5 (PN 4316064P) were used. To normalise differences in sample sizes and the
amount of RNA degradation, primers/probe for ribosomal RNA 18S (PN 4310893E) was also
applied as an endogenous control.
Total reaction volume used in the PCR amplification was 25 µl, containing 50 ng (for
target gene) or 5 ng (for endogenous control) of template cDNA. PCR was performed under
the following conditions: 50°C for 2 min, 95°C for 10 min; 50 cycles of 95°C for 15 sec and
60°C for 1 min. Analysis of a calibrator cDNA sample derived form PHA stimulated
peripheral blood lymphocytes, and controls without template were also performed on each
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PCR plate. Each measurement was set up in triplicate. The quantitative analysis was
performed using the comparative CT (∆CT) method as described in detail previously (Gibson
et al. 1996).
10. HLA genotyping (II)
HLA genotyping was performed in 11 T1D patients from peripheral venous blood sample
and in 19 T1D patients from duodenal paraffin blocks. HLA-DQB1, HLA-DQA1, and HLA-
DRB1 analysis were performed by a technique developed for screening T1D susceptibility
based on the presence of alleles associated with a risk for or with protection against T1D.
This two-step screening technique is based on the hybridisation of relevant PCR products
with lanthanide-labelled probes detected by time-resolved fluorometry (Nejentsev et al.
1999).
11. In situ detection of DNA fragmentation (ISEL) (III)
To detect cells with DNA fragmentation terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP-digoxigenin in situ 3-end labelling (ISEL) method was used as described
previously (Surh and Sprent 1994). Briefly, eight-µm sections were fixed in acetone, washed
with PBS and incubated with 0.3% H2O2 in methanol to eliminate endogenous peroxidase
activity. The sections were preincubated with 1 x terminal transferase reaction buffer (Roche
Diagnostics) containing 1mM CoCl2 for 10 min at room temperature. The apoptotic DNA
fragments were 3'-end labelled with digoxigenin-11-ddUTP (0.5µM, Roche Diagnostics) by
TdT reaction (TdT enzyme 375 U/ml) in 1 x reaction buffer containing 45µM ddATP
(Amersham Pharmacia) and 1mM CoCl2 (Roche Diagnostics) at 37°C for 1 hour. Following
washes and blocking of nonspecific binding with 2% blocking reagent, the sections were
incubated with horseradish peroxidase-conjugated anti-digoxigenin antibody (1:200, Roche
Diagnostics) overnight at +4°C. The colour was developed with chromogen
diaminobenzidine (Sigma) and counterstaining was performed with Harris haematoxylin. For
negative controls the TdT enzyme or labelled nucleotides were replaced by distilled water,
and for positive controls the sections were incubated with DNAse (1-10 IU/ml) at 37°C for
15 min prior to the TdT reaction.
The sections of the patients were always processed in parallel with the controls and a
total of three sections per patient were analysed. The number of enterocytes with DNA
fragmentation was calculated through a calibrated graticule as percentages of positive cells
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along the surface epithelium and in the crypt epithelium, with a minimum of 200 cells
counted in each compartment.
12. Histopathological analysis (III)
The intestinal biopsy samples were stained routinely by haematoxylin and eosin and analysed
by one pathologist (Riitta Karikoski) blinded for the clinical data. The histological grading of
intestinal GvHD ranged from signs of apoptosis and infiltration of intraepithelial
lymphocytes (grade 1) through exploding crypts (grade 2) and loss of crypts (grade 3), to
total sloughing off of the epithelium (grade 4).
13. Statistical analysis (I-IV)
Differences in the parameters studied were revealed by the Kruskall-Wallis analysis of
variance when more than two groups were compared, and by the Mann-Whitney U-test when
two groups were compared (I-IV). The correlation between proliferation and apoptosis
markers in the SCT patients was analysed with the Spearman correlation (III). Calculations
were done on a PC using SPSS software (SPSS Inc, Chigaco, IL, USA). Cell densities for
each group were expressed as median values, and because of the small sizes of the study
groups, values outside the 25 to 75 percentiles were considered abnormal for the group. A P-
value < 0.05 was considered significant.
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RESULTS
To study immunologic markers and expression patterns of cytokines in immunologically
mediated inflammation, small intestinal biopsies were obtained from patients with potential
CD (I), T1D (II), patients undergoing SCT (III), and patients with food allergy (IV). The
intestinal specimens were studied using immunohistochemistry, in situ hybridisation, RT-
PCR and in situ 3'-end labelling (ISEL).
The results from immunohistochemical stainings and in situ hybridisation of studies I-
IV are combined in this section and presented separately for each parameter. In the control
group, the normal control patients from study I (n=8) are pooled with the five additional
control patients from study II (total n=13), if not mentioned otherwise. The results of SCT
study patients (n=12) and clinical GvHD control patients (n=3) are presented in the figures in
the same group at 6 weeks (n=15) and at 3 months (n=11).
1. Densities of intraepithelial T-cells (I-IV)
Intraepithelial T-cells were stained with mAbs to CD3, γδTCR, and αβTCR in all the
specimens. From previous studies it is known that the numbers of IELs, especially of γδTCR+
cells, are highly increased in CD and to a lesser extent in family members of CD patients, as
well as in patients with delayed type food allergy. We found increased densities of CD3+,
γδTCR+, and αβTCR+ IELs in potential CD and CD patients in studies I-II, regardless of
associated T1D (Figure 4). The IEL infiltration was more pronounced in clinical CD than in
potential CD. We also found increased densities of CD3+ (P=0.008) and γδTCR+ (P=0.008),
but not of αβTCR+ IELs in the bulb of duodenum from CD patients in study IV when
compared to controls. The densities were somewhat lower than in the duodenal biopsies from
patients with CD in studies I and II (Figure 4). Furthermore, the patients with untreated food
allergy had a higher density of γδTCR+ IELs than the controls in study IV (P=0.01). The
densities of all three IEL subtypes were as low in SCT patients as in normal controls. The
density of αβTCR+ IELs was significantly lower in SCT patients than in controls at both
timepoints (P=0.001 and 0.007, respectively) (Figure 4C).
We investigated the IELs staining positively for IFN-γ in studies II and III. Although
the densities of IELs stained with T-cell markers were not increased in SCT patients, the
density of IFN-γ+ IELs was higher in SCT study patients and clinical GvHD control patients
at both 6 weeks and 3 months than in controls (P<0.01 in all comparisons). We also found a
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higher density of IFN-γ+ IELs in T1D patients with CD or potential CD than in controls or
T1D patients with normal mucosa (P<0.006 in all four cases) (Figure 4D).
We further examined the proportion of CD4+ and CD8+ T-cells in the epithelium and
lamina propria in study IV. We found no difference in the density of CD4+ IELs between the
study groups (medians 0.8-1.7 cells/mm, corresponding to 2.8-8.4% of CD3+ IELs), whereas
the density of CD8+ IELs was significantly increased in CD patients when compared to
controls (P=0.032), patients with untreated food allergy (P=0.005), or patients with treated
food allergy (P=0.018).
Figure 4. Densities of CD3+, γδTCR+, αβTCR+, and IFN-γ+ intraepithelial lymphocytes (IELs) in
the different study groups. The individual results are shown as positively staining cells/mm of
surface epithelium. The Roman numerals at the top of the figures indicate the number of the study.
The medians are indicated by horisontal lines for each study group. Study groups: Pot CD, potential
CD; T1D+norm, T1D patients with normal duodenal mucosa; T1D+pot CD, T1D patients with
potential CD; T1D+CD, T1D patients with CD; SCT 6 wk, patients 6 weeks after SCT; SCT 3 mo,
patients 3 months after SCT; FA co, control patients included in food allergy study; tFA, patients with
treated food allergy; uFA, patients with untreated food allergy; FA CD, CD patients included in food
allergy study.
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2. Densities of T-cells in the lamina propria (I-IV)
We counted the densities of lamina propria CD3+, γδTCR+ and αβTCR+ T-cells in the same
microscopical slides as the IELs. Generally, the lamina propria T-cells did not show as large
a variation between the study groups as IELs did (Figure 5). T1D patients with potential CD
or CD had the highest densities of all T-cell subtypes. In study I we found an increased
density of γδTCR+ cells in CD patients when compared to controls (P=0.038), whereas in
study II all three cell subtypes were increased in T1D patients with CD (P<0.001 in all cases)
or potential CD (P=0.009, P=0.006, and P=0.048, respectively) when compared to normal
controls (Figure 5). In addition, the numbers of all three cell subtypes were higher in T1D
patients with CD than in T1D patients with normal mucosa (P=0.015, P=0.0028 and P=0.015,
respectively).
We found a significantly lower density of γδTCR+ cells in biopsies of SCT patients at 6
weeks than in controls (P=0.013) (Figure 5B). By the time of the second endoscopy, the
median density of lamina propria γδTCR+ cells had increased from 22.1 (range 13.6-58.6) to
42.5 (range 21.6-141.1) positive cells/mm2 (p=0.017) in SCT patients. The clinical GvHD
patients showed a higher density of γδTCR+ cells at 6 weeks than SCT study patients
(P=0.009) (Figure 5B).
In study IV we observed an increased density of CD3+ cells in CD patients when
compared to patients with treated food allergy (P=0.048), but not when compared to patients
with untreated food allergy or normal controls (Figure 5A). The density of CD4+ or CD8+
cells in the lamina propria did not differ between the study groups in study IV.
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Figure 5. Densities of CD3+, γδTCR+, and αβTCR+ lamina propria lymphocytes (LPL) in the
different study groups. The individual results are shown as positive cells/mm2 of lamina propria.
The Roman numerals at the top of the figures indicate the number of the study. The medians are
indicated by horisontal lines for each study group. Study groups: Pot CD, potential CD; T1D+norm,
T1D patients with normal duodenal mucosa; T1D+pot CD, T1D patients with potential CD;
T1D+CD, T1D patients with CD; SCT 6 wk, patients 6 weeks after SCT; SCT 3 mo, patients 3
months after SCT; FA co, control patients included in food allergy study; tFA, patients with treated
food allergy; uFA, patients with untreated food allergy; FA CD, CD patients included in food allergy
study.
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3. Expression of cytokines detected by immunohistochemistry (I-IV)
The expression of cytokines were studied using monoclonal antibodies against IL-1α, IL-2,
IL-4, IFN-γ, and TNF-α. We considered only typical paranuclear stainings as positive. In
study IV only IL-4 and IFN-γ were investigated. Because of different batches used in study I
vs. the other studies for all cytokines but IL-2, the data from study I can not directly be
compared with the data from other studies. This is represented by the dotted line in Figures 6
and 7. Furthermore, the results of potential CD and CD patients are compared with the results
of the original normal control group of study I.
Th1- and Th2-type cytokines
The densities of IFN-γ+ cells were generally higher, while the densities of IL-4+ cells were
generally lower in study I than in the other three studies, one of the explanations probably
being the different antibody batches used. When looking at the Th1 vs. Th2 balance in the
studies, the general finding is that CD patients show higher densities of IFN-γ+, IL-2+, and IL-
4+ cells, regardless of associated T1D (Figure 6).
In study I the potential CD and CD patients expressed higher densities of IL-2+ (P=0.043 and
P=0.028), IFN-γ+ (P=0.009 and P<0.001) and IL-4+ cells (P=0.034 and P=0.021) than the
controls (Figure 6). When potential CD patients were divided into two groups according to
normal (n=4) or increased numbers of IELs (n=6), the potential CD patients with high
numbers of IELs showed a higher density of IFN-γ positive cells, but the difference did not
reach statistical significance (P=0.088).
In study II the T1D patients with CD had higher densities of IFN-γ+, IL-2+, and IL-4+
cells than both the normal controls and the T1D patients with normal mucosa (P<0.002 in all
cases), and higher density of IL-4+ cells than T1D patients with potential CD (P=0.002).
Furthermore, the T1D patients with normal mucosa or potential CD showed increased IL-4
densities when compared to controls (P=0.031 and P=0.027) (Figure 6).
The density of IL-2+, IL-4+ and IFN-γ+ cells did not differ between the biopsies
obtained at 6 weeks from SCT patients and normal controls in study III. However, at the time
of the second biopsy 3 months after SCT, the density of IFN-γ+ cells was lower than in the
normal controls (P=0.001, SCT 3 months vs. controls), and the density of IL-4 cells was
greater (P=0.001, SCT 3 months vs. controls) (Figure 6). The clinical GvHD patients did not
differ from the SCT study patients with respect to any of the assessed cytokines, but showed
a lower density of IL-2+ cells than the controls (P=0.002).
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We found an increased density of IFN-γ+ cells in patients with untreated food allergy
when compared to normal controls (P=0.018). Although the cell density tended to be higher
in untreated than in treated food allergy patients, the difference was not significant (P=0.053).
Figure 6. Densities of IFN-γ+, IL-2+, and IL-4+ cells in the lamina propria detected by
immunohistochemistry. The individual results are shown as positive cells/mm2 of lamina propria.
The Roman numerals at the top of the figures indicate the number of the study. The dotted vertical
lines indicate that different batches of antibodies for IFN-γ and IL-4 were used in study I vs. the other
studies. The medians are indicated by horisontal lines for each study group. Study groups: T1D
controls, control patients included in study II; T1D+norm, T1D patients with normal duodenal
mucosa; T1D+pot CD, T1D patients with potential CD; T1D+CD, T1D patients with CD; SCT 6 wk,
patients 6 weeks after SCT; SCT 3 mo, patients 3 months after SCT; FA co, control patients included
in food allergy study; tFA, patients with treated food allergy; uFA, patients with untreated food
allergy; FA CD, CD patients included in food allergy study; Pot controls, control patients in study I;
Pot CD, potential CD.
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Proinflammatory cytokines
The densities of the proinflammatory cytokines IL-1α and TNF-α are shown in Figure 7. We
did not find any difference in the density of IL-1α+ cells between the groups in study I,
whereas we found higher numbers of TNF-α+ cells in CD patients than in controls or
potential CD patients (P=0.001 and P=0.012). Although the potential CD patients with
increased IELs expressed a higher density of TNF-α+ cells than those with normal density
did, the difference failed to reach statistical significance (P=0.088).
We found higher densities of IL-1α and TNF-α positive cells in T1D patients with CD
than in controls (P<0.001 and P=0.050) or T1D patients with normal mucosa (P=0.002 and
P<0.001). In addition, the T1D patients with normal mucosa or potential CD showed
increased densities of IL-1α+ cells when compared to controls (P=0.031 and P=0.006)
(Figure 7).
We observed greater densities of IL-1α+ cells in SCT specimens at 6 weeks and 3
months than in controls (P=0.005 and P=0.002), whereas the densities of TNF-α+ cells were
lower than in controls (P=0.010 and P=0.031) (Figure 7). The numbers of IL-1α+ and TNF-
α+ cells did not differ between the study SCT study patients and clinical GvHD patients (data
not shown).
Figure 7. Densities of IL-1α+ and TNF-α+ cells in the lamina propria detected by
immunohistochemistry. The individual results are shown as positive cells/mm2 of lamina propria.
The Roman numerals at the top of the figures indicate the number of the study. The dotted vertical
lines indicate that different batches of antibodies were used in study I vs. the other studies. The
medians are indicated by horisontal lines for each study group. Abbreviations of study groups are the
same as in Figure 6.
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4. RNA in situ hybridisation for IL-4 and IFN-γ mRNA detection (I-IV)
We performed radioactive RNA in situ hybridisation for IL-4 and IFN-γ in serial sections
from the same samples that were used for immunohistochemical stainings. The method was
the same in study I-IV, but two different interpretations were used (see page 52).
We found positive IL-4 mRNA hybridisation signals mainly in the lamina propria, with
little or no signal in the surface epithelium. Mononuclear cells expressing IL-4 mRNA were
present in all samples, although more sparsely distributed than IFN-γ mRNA expressing cells.
In situ hybridisation with the antisense probe for IFN-γ revealed that positive cells were
found mainly in the superficial lamina propria, and occasionally in the deeper parts,
regardless of the underlying disease. IFN-γ mRNA expressing cells were also found in the
intraepithelial compartment throughout the surface and the crypt epithelium, but the median
was only 1 cell/10 areas of surface epithelium in normal controls.
In study I the potential CD patients showed a lower relative intensity of IL-4, but
higher of IFN-γ when compared to controls (P=0.008 and P=0.009). In addition, CD patients
showed a higher intensity of IFN-γ than controls (P=0.035) (Figure 8).
The density of IL-4 mRNA expressing cells was significantly greater in all three T1D
study groups when compared to normal controls in study II (P<0.001 for all comparisons). In
addition, T1D patients with CD or potential CD also showed a stronger expression of IL-4
mRNA than T1D patients with normal mucosa (P=0.010 and P=0.030) (Figure 8D). Densities
of IFN-γ mRNA expressing cells in the lamina propria were significantly greater in all T1D
groups than in controls. However, among the T1D patients IFN-γ mRNA positive cells were
5 and 2.7 times more abundant in T1D patients with CD or potential CD than in those with a
normal intestine. Further, the densities of IFN-γ mRNA positive cells were significantly
increased in T1D patients with CD compared to the other two T1D study groups (P<0.001
and P=0.019). We also found a significantly increased density of IFN-γ mRNA positive IELs
in T1D specimens with CD or potential CD when compared to normal T1D specimens
(P<0.001 and P=0.006) or controls (P<0.001 for both comparisons) (data not shown).
In study III both SCT groups had significantly lower densities of IL-4 mRNA
expressing cells than controls did (P<0.001 for both comparisons), whereas the densities of
IFN-γ mRNA expressing cells did not differ in the groups in the lamina propria or in the
epithelial compartment (Figure 8).
CD patients in study IV had an increased intensity of IL-4 and IFN-γ when compared to
treated food allergy patients (P=0.010 and P=0.017) and controls (P=0.029 and P=0.016), but
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when compared to untreated food allergy patients only the intensity of IL-4 was higher
(P=0.006) (Figure 8A and 8C).
Figure 8. Expression of IFN-γ and IL-4 mRNA detected by in situ hybridisation. The individual
results are shown as relative intensity in A and C, and as the number of positive cells/area of lamina
propria in B and D. The Roman numerals at the top of the figures indicate the number of the study.
The medians are indicated by horisontal lines for each study group. The study groups are: Pot
controls, control patients in study I; Pot CD, potential CD; FA co, control patients included in food
allergy study; tFA, patients with treated food allergy; uFA, patients with untreated food allergy; FA
CD, CD patients included in food allergy study; T1D controls, control patients included in study II;
T1D+norm, T1D patients with normal duodenal mucosa; T1D+pot CD, T1D patients with potential
CD; T1D+CD, T1D patients with CD; SCT 6 wk, patients 6 weeks after SCT; SCT 3 mo, patients 3
months after SCT.
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5. Taqman real time PCR analysis of cytokines, CCR-4 and CCR-5 (II)
Signals of IL-2, IFN-γ, TNF-α, CCR-4 and CCR-5 mRNA were detectable by RT-PCR in all
duodenal specimens. IL-4 mRNA was, however, not detectable in the biopsies of normal
controls, whereas we could detect IL-4 in 3 of 16 of the T1D specimens with normal mucosa,
in 3 of 8 potential CD, and in 5 of 8 of the T1D patients with CD. The amount of IFN-γ
mRNA was again significantly greater in T1D patients with CD or potential CD compared to
T1D patients with normal mucosa (P<0.001 and P=0.001) and controls (P<0.001 and
P=0.002), correlating with the degree of CD. Additionally, CCR-4 was expressed in
significantly higher amounts in T1D patients with CD than in T1D patients with normal
duodenal mucosa (P=0.010). We found expression of CCR5 in all investigated specimens,
but we did not find any difference between the study groups. The individual results of CCR4
and CCR5 mRNA expression are shown in Figure 9.
6. Proliferation of epithelial cells (I-IV)
Proliferating cells were stained for Ki-67 and the percentage of positive crypt epithelial cells
were counted in at least 200 crypt cells. The typical stainings are shown in Figure 10A and
the individual results in Figure 10B. We found increased proliferation rates in CD patients,
T1D patients with potential CD or CD, SCT patients and in untreated food allergy patients.
We found a higher percentage of Ki-67 positive crypt cells in biopsies of patients both after 6
weeks and 3 months after SCT than in normal controls (P=0.002 and P<0.001) (Figure 10B).
Specimens from SCT study patients and clinical GvHD patients showed very high rates of
Figure 9. Expression of CCR4 and
CCR5. Chemokine receptor 4 and -5
specific mRNA detected by RT-PCR in
duodenal specimens of healthy controls
(n=7), type 1 diabetes patients with
normal duodenal mucosa (T1D+norm,
n=16), with potential coeliac disease
(T1D+pot CD, n=8), or with coeliac
disease (T1D+CD, n=7).
Individual results are shown as relative
amount (2-∆∆CT) of target compared to
the calibrator, both normalised to an
endogenous reference (18S). Horisontal
lines show medians for each study
group.
RESULTS
___________________________________________________________________________
66
proliferation, with median values of 42% and 48% at 6 weeks, and 37% and 54% at 3
months. CD patients in study I had a significantly higher expression of Ki-67 than potential
CD patients (P=0.012) or controls (P=0.001) (Figure 10). T1D patients with CD and potential
CD showed a higher percentage of Ki-67+ cells than controls (P=0.001 and P=0.019) or T1D
patients with normal mucosa did (P=0.003 and P=0.011). Finally, we also found higher
positive expression in CD patients (P=0.030) and patients with untreated food allergy
(P=0.026) than in treated food allergy patients in study IV.
Figure 10. Proliferation of crypt epithelial cells. A. Proliferation of crypt epithelial cells was
detected by immunohistochemical staining with Ki-67. The typical staining in specimens of a control
patient (study I), a patient with CD (study I), and a SCT patient 6 weeks after transplantation (study
III) is shown. Increased positive expression can be seen in the crypts of CD and SCT specimens when
compared to the normal control (carbatzole-haematoxylin stain, original magnification x100). B. The
percentages of Ki-67 positive crypt epithelial cells are shown as individual results in the different
study groups. The medians are indicated by horisontal lines. Study groups: Pot CD, potential CD;
T1D+norm, T1D patients with normal duodenal mucosa; T1D+pot CD, T1D patients with potential
CD; T1D+CD, T1D patients with CD; SCT 6 wk, patients 6 weeks after SCT; SCT 3 mo, patients 3
months after SCT; FA co, control patients included in food allergy study; tFA, patients with treated
food allergy; uFA, patients with untreated food allergy; FA CD, CD patients included in food allergy
study.
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7. Apoptosis of epithelial cells (III)
As we found a high proliferation rate of crypt eptihelial cells in specimens from SCT patients,
we also performed apoptosis staining, in order to determine if the high rate of renewal was
due to increased apoptosis. We used the ISEL staining method, which detects fragmented
DNA, to detect apoptosis. Representative positive staining is shown in Figure 11A. We
counted the percentage of ISEL positive epithelial cells in both the crypt and surface
epithelium. The individual results are shown in Figure 11B.
Figure 11. Apoptosis of epithelial cells after stem cell transplantation (SCT). A. Apoptosis was
detected by in situ 3'-end labelling (ISEL) of apoptotic DNA in duodenal biopsy specimens. ISEL
analysis revealed increased numbers of epithelial cells undergoing apoptosis both in the crypts and
surface epithelium in specimens from SCT study patients (SCT) than in specimens from normal
controls (control) (diaminobenzidine-haematoxylin stain, original magnification x200). B. Percentage
of apoptotic crypt and surface epithelial cells detected by ISEL in duodenal specimens of normal
controls, SCT patients at 6 weeks, and SCT patients at 3 months. Horisontal lines show medians for
each study group. C. Proliferation detected by Ki-67 and apoptosis of crypt epithelial cells detected by
ISEL was present in the same duodenal specimens of normal controls (r=0.44, P=0.01 Spearman
correlation) (black triangles, n=12), SCT patients at 6 weeks (black circles, n=10), SCT patients at 3
months (open circles, n=7), and clinical GvHD patients at 6 weeks (black boxes, n=2).
RESULTS
___________________________________________________________________________
68
We found a higher percentage of apoptotic cells both in the crypts (P<0.001 and
P=0.002) and in the surface epithelium (P<0.001 and P=0.001) in SCT patient groups when
compared to controls (Figure 11B). In the villi, we found apoptotic cells only in the tips in
normal controls (median 2.3% of the epithelial cells in the whole villous), while the apoptotic
cells were scattered along the whole villous height in SCT specimens (median 8.6% at 6
weeks and 7.6% at 3 months). The same samples showed an increased turnover rate detected
by Ki-67 and increased apoptosis of the crypt cells, as shown in Figure 11C (P=0.01,
Spearman correlation).
8. Expression of HLA-DR, HLA–DP, and ICAM-1 (I-IV)
We found a significantly increased expression of HLA-DR in the epithelium of CD patients,
in all T1D patients, in SCT patients, and in food allergy patients. We also found an increased
staining of HLA-DP in CD patients, T1D patients, SCT patients at 6 weeks, and in treated
food allergy patients when compared to normal controls. The expression of ICAM-1 was
increased in the lamina propria of all T1D patients and in CD patients of study I and IV.
In studies I-III the expression of HLA-DR and HLA-DP antigens was graded from 2 to
6 according to their intensity and cellular distribution, while the staining was determined by
point-counting in study IV (see page 51). Only the data from studies I-III are presented in
Table 8.
Table 8. Expression of HLA-DR, HLA-DP, and ICAM-1 in studies I-III.
Study Study group HLA-DR HLA-DP ICAM-1
I-III Normal controls 2 (2-6) 3 (2-5) 2 (1-3)
I Potential CD 2 (2-5) 2 (2-6) 2 (1-3)
I CD 6 (2-6) 6 (5-6) 3 (3-3)
II T1D + normal mucosa 5.5 (5-6) 5 (4-5) 3 (2-3)
II T1D + potential CD 6 (5-6) 5 (5-5) 3 (3-3)
II T1D + CD 6 (5-6) 6 (5-6) 3 (3-3)
III SCT 6 weeks 5 (2-6) 5 (2-6) 2 (2-3)
III SCT 3 months 4 (2-6) 4 (2-6) 2 (2-3)
Expression was analysed by immunohistochemistry. Values are given as
median (range) for the different groups.
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9. HLA-genotyping (II)
We found the DQB1*0201 allele in 6/16 T1D patients with normal mucosa (37.5%), of
whom three also were positive for DQB1*0302. Four of the patients were positive for
DQB1*0302 alone without protective alleles. Of the remaining patients, one was positive for
DQB1*0301, one for DQB1*0602, one was not genotyped, and two were negative for all the
alleles tested. Of the eight T1D patients with newly diagnosed CD, five were positive for
DQB1*0201 (63%), of which two also were positive for DQB1*0302. One of the T1D
patients with CD was positive for DQB1*0602 and the last two were negative for all the
alleles tested. Six of the eight T1D patients with potential CD were positive for DQB1*0201
(75%), of whom two also were positive for DQB1*0302. The remaining two patients were
positive for DQB1*0302 alone. The heterodimer HLA-DQ2 (DQB1*0201/DQA1*0501)
associated with CD was carried by 4/8 T1D patients with CD and by 6/8 T1D patients with
potential CD.
HLA-genotype associations
T1D patients carrying both the HLA-DR3 and HLA-DQ2 antigens (13 patients; 4/8 with CD,
6/8 with potential CD, and 3/16 with normal mucosa) showed higher densities of CD3+ and
γδTCR+ cells in the lamina propria (P=0.041 and P<0.001) and of γδTCR+ cells in the surface
epithelium (P=0.023) than those negative for the alleles. The density of IL-4+ cells, both
protein and mRNA expressing, was equal in both DR4 positive and negative patients. The
density of IL-2 positive cells was somewhat lower in DR4 positive than in negative patients
(P=0.049).
10. Expression of adhesion molecules and CD25 (IV)
The densities of α4β7 and CD11a positive cells were determined both in the epithelial
compartment and in the lamina propria in study IV. We could not find any difference in the
densities of α4β7+ IELs between the study groups, whereas the density of CD11a+ IELs was
significantly higher in CD patients than in patients with treated food allergy (P=0.048)
(Figure 12A). The density of α4β7+ cells in the lamina propria was increased in CD patients
when compared to the two food allergy study groups (P=0.048 and P=0.005, respectively),
but not when compared to controls. Furthermore, the density of CD11a+ cells was higher in
CD patients than in treated food allergy patients (P=0.048) and controls (P=0.032) (Figure
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12B). Surprisingly, the numbers of CD25 (IL-2R) expressing cells in the lamina propria did
not differ between the study groups (Figure 12B).
Figure 12. Expression of adhesion molecules and CD25 in food allergy.
A. Densities of α4β7 and CD11a positive cells in the surface epithelium are expressed as positive
cells/mm epithelium. B. Densities of α4β7, CD11a, and CD25 positive cells in the lamina propria are
expressed as positive cells/mm2 lamina propria. The medians are indicated by horisontal lines for each
study group; FA co, control patients; tFA, patients with treated food allergy; uFA, patients with
untreated food allergy; FA CD, CD patients.
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DISCUSSION
1. Methodological aspects (I-IV)
Patients and controls
Studies using human tissues have their limitations both because of ethical and practical
reasons. The children included in the normal control group all had clinical indications for
investigation, which may affect the immunologic markers studied. However, as the controls
were chosen according to the following criteria they represent as normal available controls as
possible. The exclusion criteria for the controls were: no history of CD or DH in the family,
no medication and generally healthy, i.e., no chronic disease, and negative endomysium and
tissue transglutaminase antibody tests. In addition, they all had normal morphology and
normal density of intraepithelial lymphocytes in the small intestinal biopsy specimen taken
for routine histology, which was examined independently by a specialist in pathology, as well
as in the biopsy specimen used in our study. At the end of April 2004, none of the controls
still affiliated to the Hospital for Children and Adolescents, Helsinki University Central
Hospital, has developed CD.
The intestinal biopsy specimens obtained during gastroscopy from paediatric patients
are small, which limits the number of markers that can be investigated. We used frozen tissue
samples, in which the antigenic epitopes should be preserved in their native forms. The delay
before the tissue was snap frozen in liquid nitrogen or the duration of sample storage before
use may affect the variables measured, but we did not observe any correlation between the
duration of sample storage at -70°C and the levels of markers investigated.
The biopsies in study IV were obtained from the duodenal bulb, which differs from the
rest of the duodenum as well as from the duodenal mucosa. Therefore, the results from this
study can not be directly compared with the results from studies I-III.
Methods
We have described cytokine positive cells in small intestinal biopsies by
immunohistochemistry and radioactive in situ hybridisation. The methods have their
limitations, not allowing recognition of the cell types involved in the cytokine expression.
Double staining methods could, thus, be more informative. Difficulties with cytokine staining
are well described and are due to both technical difficulties and interpretation (Arend and
Dayer 1990, Hoefakker et al. 1995, van der Loos et al. 2001). We tested two antibodies
against TGF-β (clone 1D11, R&D systems and T9429, Sigma) and three against IL-10
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(clones JES3-9D7, JES3-12G8 and 19F1, Mabtech). Due to inconsistency and extensive
background staining, which made interpretation unreliable, we did not proceed with these
cytokines. The surprisingly different staining of the various batches used for IL-1α, IL-4,
IFN-γ and TNF-α in our study, furthermore raises concern about the reproducibility of
immunohistochemical stainings for cytokines. Consequently, results from cytokine
immunohistochemistry must be interpreted with considerable caution.
Radioactive in situ hybridisation has its limitations as well: it is time consuming and as
with immunohistochemical techniques, similar difficulties in interpretation exist. In order to
overcome the subjectivity in interpretation, we developed a semiquantitative evaluation
system used in studies I and IV. Still, interpretations of both methods are subjective.
Although the interpretation of the slides was performed blinded with regard to the clinical
data, the morphology of CD or GvHD is obvious, making the interpretation semi-blinded.
2. Densities of intraepithelial T-cells (I-IV)
We observed an increased density of IELs in potential CD and CD specimens, also in those
of patients with additional T1D, which is in agreement with previous studies (Savilahti et al.
1990, Spencer et al. 1991, Kaukinen et al. 1998, Iltanen et al. 1999, Järvinen et al. 2003). We
also found a moderate increase of γδTCR+ IELs in specimens from patients with untreated
food allergy, which is in agreement with earlier studies (Kokkonen et al. 2000, Savilahti
2000).
While on a gluten containing diet, family members in study I and T1D patients with
potential CD in study II, had almost as high densities of γδTCR+ IELs as CD patients. Still,
the intestinal biopsies of potential CD cases showed a normal duodenal architecture. The
presence of gluten in the diet combined with high numbers of γδTCR+ cells in the epithelium
do thus, not necessarily lead to villous atrophy, which indicates that genetic factors and
additional environmental agents play a further role in the manifestation of the disease. The
increase of IELs in duodenal biopsies of patients with T1D is probably associated with the
risk for developing CD, rather than related to T1D, as the T1D patients with increased IELs
also had circulating tissue transglutaminase and/or endomysium antibodies. Moreover, the
T1D patients without positive CD autoantibodies did not differ from the controls regarding
the number of IELs, indicating that an increase in the IEL count is not associated with T1D.
Notably, we also found increased densities of IFN-γ positive IELs in patients with T1D
and potential CD or CD, which is in agreement with recent studies on CD patients (Forsberg
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et al. 2002, Olaussen et al. 2002). Paediatric CD patients were also shown to have an
increased IFN-γ production intraepithelially when they were on a gluten-free diet, symptom
free and their villous atrophy had resolved (Forsberg et al. 2002). This indicates continued
activation of IELs in CD. Whether it is a predisposing factor for CD or a consequence of
previous episodes of active CD, or due to a failure to totally eliminate gluten from the diet is
not known. Recently, IFN-γ was shown to increase the production of chemoattractants for
IELs by intestinal epithelial cells (Dwinell et al. 2001, Shibahara et al. 2001). Consequently,
the increased amounts of IFN-γ in the epithelial compartment might be due to both increased
recruitment and activation of IELs. IFN-γ is likely to cause changes in the epithelial cells. It
can induce in them the ability to function as APC (Hershberg and Mayer 2000) and,
secondly, increase the permeability of the epithelial monolayer (Madara and Stafford 1989).
The density of IELs in our patients study SCT patients was surprisingly low. The
density of γδTCR+ IELs in clinical GvHD patients was increased, indicating that increased
IEL count is associated with the pathogenesis of acute GvHD and not with the general
condition in the intestine after allogeneic SCT. Our finding in GvHD patients is consistent
with murine GvHD studies. Increased IELs have been a characteristic component of intestinal
GvHD, where an increased IEL count is one of the earliest detectable signs, occurring within
24 hours after inducing GvHD in a neonate or in irradiated mice (Mowat et al. 1988). Despite
of normal density of IELs the numbers of IFN-γ+ IELs was increased in SCT study patients at
both 6 weeks and 3 months after SCT when compared to normal controls. This indicates that
the IELs, although of a normal density, are activated either because of the conditioning
regimen, preceding immunosuppression, or an accompanying infection.
The function of intraepithelial γδTCR+ cells is not fully understood, but there are many
postulated ones (Hayday 2000, Guy-Grand and Vassalli 2002). First, they are thought to act
as cytotoxic cells against microbial pathogens via lysis of infected epithelial cells, and
removal of damaged or transformed epithelial cells (Lundqvist et al. 1996). Second, they
have been shown to support the growth of epithelial cells and the maintenance of the
epithelial barrier integrity through their production of keratinocyte growth factor (Boismenu
and Havran 1994). Thirdly, they have been suggested to have immunoregulatory functions
through their production of cytokines, including IL-2, IFN-γ, TNF-α, IL-10, and TGF-β
(Boismenu et al. 1996). Furthermore, it has been shown that depletion of γδTCR+ IELs
improves the enteropathy of murine GvHD (Sakai et al. 1995), but abrogates oral tolerance
(Fujihashi et al. 1992). Our results on increased densities of IELs in patients with CD, GvHD
and untreated food allergy are based on descriptive studies and we can therefore only
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hypothesise on the functions of the cells. The increase of IELs may reflect different functions
of the IELs in the investigated diseases. The increase in IELs in GvHD may reflect their
cytotoxic functions against transformed or otherwise stressed epithelial and stromal cells due
to the conditioning regimen. The IELs may, on the other hand, protect the intestinal mucosa
from chronic exposure to damaging agents such as gluten in CD and allergenic food antigens
in food allergy.
3. Expression of HLA-DR and HLA-DP (I-IV)
Our data on increased expression of MHC class II HLA-DR and HLA-DP molecules in CD
patients is in line with earlier reports (Arnaud-Battandier et al. 1986, Ciclitira et al. 1986,
Arato et al. 1987, Marley et al. 1987, Kelly et al. 1988). We observed increased expression of
these molecules in those family members of CD patients that had an increased IEL count,
whereas the expression was normal in family members with a normal IEL count. Increased
staining was documented in approximately half of the first-degree relatives of CD patients
investigated in one previous report (Holm et al. 1994), which is in agreement with our results.
We also found increased expression of HLA-DR and HLA-DP antigens in the duodenal
mucosa of patients with T1D in study III, regardless of the mucosal architecture, HLA
genotype, and duration of T1D. The increased expression in our T1D patients confirms the
findings of an earlier study (Savilahti et al. 1999). Additionally, we observed an increased
expression HLA-DR in the crypts of untreated food allergy patients.
The increased expression of these molecule in our SCT patients, is in accordance with
an earlier report describing up-regulation of HLA-DR in enterocytes and keratinocytes after
allogeneic SCT (Sviland et al. 1988). Notably, we also found increased expression of HLA-
DR in patients without histologically proven GvHD and the increase was still present 3
months after SCT.
The increased expression of MHC class II molecules is one of the first signs of immune
activation in the intestine of CD patients. Installation of gluten into the jejunum of treated CD
patients induced HLA-DR expression in crypt epithelial cells within an hour in one study
(Ciclitira et al. 1986), whereas stimulation of coeliac small intestine biopsies with gluten
showed induced expression of HLA-DR and ICAM-1 molecules on lamina propria
macrophages and epithelial cells before T-cells were seen to migrate to the subepithelial
compartment (Maiuri et al. 1996). This expression is probably induced by the secretion of
IFN-γ by activated Th1 cells (Skoskiewicz et al. 1985), but also IL-4 has been postulated to
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increase the expression of MHC class II molecules. The increase in HLA-DR and HLA-DP
staining in our studies was associated with increased expression of either IFN-γ (in patients
with potential CD, CD or untreated food allergy) or IL-4 (in patients with T1D or patients
undergoing SCT), supporting the regulatory function of these cytokines in the intestinal
immune response.
The expression of MHC class II molecules on normal epithelial cells has been
considered to indicate their ability to function as APCs. These functions are more limited
than those of professional APCs, but the epithelial cells could be able to activate CD4+ T-
cells via classical class II mediated pathways. If class II molecules present antigens from the
gut lumen, then their increased expression in disease states observed in this study would lead
to an increase in the presentation of the antigens to the gastrointestinal immune system. This
may cause further inflammation and even greater presentation of luminal antigens, leading to
a vicious circle. How the expression of MHC class II molecules relates to the pathogenesis of
the diseases investigated is out of scope for this study, but the increased expression of these
molecules certainly indicates that a degree of immune activation is present.
4. Cytokine expression in potential CD (I)
We have demonstrated that positive CD autoantibodies and a high density of γδTCR positive
cells in the epithelium were associated with the presence of increased densities of TNF-α and
IFN-γ positive cells in the lamina propria of family members of CD or DH patients with
normal duodenal structure. To the best of our knowledge no other report has been published
confirming our results, but the involvement of IFN-γ and TNF-α in overt CD is well
established. Recent reports have further confirmed the involvement of a Th1 deviation in CD.
IL-15 has been suggested to promote Th1 activation (Maiuri et al. 2000, Maiuri et al. 2003),
whereas increased expression of IL-18 and other markers of Th1 polarisation was
documented in another study (Salvati et al. 2002). According to a recent report, T-cells from
active coeliac mucosa did not show increased levels of TNF-α mRNA, suggesting that
macrophages are the likely source of TNF-α in CD (Forsberg et al. 2002). This is in
agreement with our immunohistochemical stainings showing that TNF-α+ cells have a large
cytoplasm.
Our data on IL-2 expression in samples of CD and potential CD patients, not showing
any difference between the study groups, may be a sign of long-standing immune activation.
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In agreement with our results, Forsberg et al. found no increase of IL-2 mRNA in paediatric
CD patients (Forsberg et al. 2002).
Expression of cytokines in family members of patients with CD vs. DH
We observed higher densities of IL-4 positive cells in the lamina propria of family members
of DH patients compared to family members of CD patients, whereas it was the opposite for
IFN-γ and TNF-α positive cells. Diverse factors could explain our findings. The studied
family members were few and individual variation may thus affect the results considerably.
The family members of DH patients were all adults, and as IL-4 has been found to
downregulate the inflammatory response, it could be hypothesised that in adult family
members the higher expression of IL-4 may indicate the protective effects of this cytokine.
Thirdly, genetic predisposition could promote the development of T-cell response towards a
Th2-type. Very few studies have evaluated the cytokine profiles in patients with CD and DH,
none of them including family members. A higher expression of IL-4 and lower expression of
IFN-γ mRNA was reported in small intestinal biopsies of DH patients than in those of CD
patients (Smith et al. 1999). The same group reported an increased production of IL-4 by
intestinal T-cell lines from patients with DH compared to patients with isolated CD (Hall et
al. 2000). These findings have not yet been confirmed by other reports, and the DH patients
studied were furthermore all on dapsone medication, which could influence the inflammation
response. Nevertheless, the difference in cytokine pattern may influence the clinical
manifestation of these two forms of gluten sensitivity.
Development of overt CD in potential CD patients and cytokine expression
The follow-up of potential CD patients since their small intestinal biopsies were included in
our study is now on the average 4.9 years at the end of April 2004. During this time two
additional patients have developed clinical CD, one 4 years (patient no 9 in the original
study), and the other almost 5 years (patient no 14) after the study biopsy was obtained. Both
of these patients showed increased IEL counts and both had endomysium antibodies at the
time of the original biopsy. Both patients also expressed high densities of IFN-γ and TNF-α
positive cells in the lamina propria, similarly as the patient with latent CD (patient no 11).
Our results support the theory that overt CD can develop on a previously normal mucosa and
that the development may be a long process. The findings on immune activation described in
our study were observable years before clinical CD developed. Our finding raises several
concerns. Firstly, should patients with potential CD already start a gluten-free diet. This is a
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well debated question but there is still no official guideline (Kaukinen et al. 2001, Mahadeva
et al. 2002, Valletta et al. 2002). A gluten-free diet has a significant impact on the everyday-
life, and as the patients are symptom-free the compliance with the gluten-free diet may be
poorer than in symptomatic CD patients. However, the continuous gluten intake in CD has
been associated with the development of other autoimmune diseases (Ventura et al. 1999, Not
et al. 2001), pointing to the importance of gluten-free diet. Increased risk for lymphoma has
not been established in the latent form of CD. Clearly, there is a need for a marker that could
predict which patients will develop overt CD in the future. None of the markers investigated
here could alone predict the progression to clinical CD. To date the presence of endomysium
antibodies has been the best positive prognostic factor, as suggested also by other reports
(Troncone 1995, Corazza et al. 1996, Troncone et al. 1996b).
5. Activation of the gut immune system in type 1 diabetes (II)
Th1/Th2 paradigm in the intestine of T1D patients
We demonstrated an increased density of IL-4 positive cells in the small intestines of T1D
patients, regardless of the duodenal architecture, the duration of T1D, or the HLA-genotype.
We had expected to find increased expression of IFN-γ in the small intestine of T1D patients,
as a systemic deviation to Th1-type immunity has been suggested both by experimental
animal studies and by studies on peripheral blood cells from T1D patients. To the best of our
knowledge no other study has investigated the cytokine expression in the intestines of T1D
patients. Intestinal cytokine profiles have been studied in experimental animal models,
demonstrating a Th1 skewing (Scott et al. 2002), but as IL-4 predominates in the murine gut
under normal conditions in opposite to the IFN-γ dominance in humans (Nagata et al. 2000,
MacDonald and Monteleone 2001), the results from animal models can not directly be
transcribed into human studies. Therefore, we can only compare our results with studies on
peripheral blood cells from T1D patients, which do not directly correlate with the cytokine
profile in the intestine or in the pancreas. However, the Th1 paradigm in T1D has been
questioned also by other studies recently. A decreased IFN-γ secretion by PBMC in newly
diagnosed T1D patients was reported in two recent studies (Mayer et al. 1999, Kukreja et al.
2002). In addition, Karlsson et al. demonstrated increased numbers of PBMC spontaneously
secreting IFN-γ in high risk relatives of T1D patients, whereas they did not find any
difference between newly diagnosed T1D patients and controls (Karlsson et al. 2000).
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Furthermore, the relatives who developed T1D displayed lower numbers of IFN-γ secreting
cells than high risk relatives that did not develop the disease during the follow-up did.
Although IL-4 has a potent inhibitory effect on the autoimmune process in the pancreas
of NOD mice (Rabinovitch and Suarez-Pinzon 2003), the mechanism by which IL-4
ameliorates autoimmunity is not understood. Recently, one group showed that IL-4 acts upon
antigen-presenting dendritic cells to decrease the cytolytic T-cell response, which prevented
autoimmunity in transgenic mice that express IL-4 via the human insulin promoter (King et
al. 2001). It has, on the other hand, also been proposed that high secretion of IL-4 contributes
to the development of beta-cell autoimmunity by enhancing self-antigen presentation
(Falcone et al. 2001).
Inflammation in the gut and insulin treatment are factors that may affect the cytokine
balance in the gut. The fact that the cytokine profiles did not differ along the progression of
T1D does not support the view that insulin treatment would explain our findings. In
agreement with our results, Vaarala et al. found increased IL-4 secretion by α4β7 expressing
PBMCs in T1D patients, 5 of whom were diagnosed only one day before sampling. The
cytokine profile did not differ among these five children when compared to the other patients
in whom blood sampling was performed later, also confirming our results (Vaarala et al.,
unpublished observations).
We did not perform any double stainings, and can therefore only hypothesise on the
origin of IL-4+ cells. According to their morphology, a proportion of the cells could be
macrophages or neutrophils rather than lymphocytes. T-cells have generally been believed to
be the main cellular source of IL-4, but recent reports have also demonstrated IL-4
production by intestinal mast cells (Maiuri et al. 1996) and by peripheral blood neutrophils
(Brandt et al. 2000). Also the appearance of IL-4+ neutrophils in the normal human skin is
induced by ultraviolet radiation (Teunissen et al. 2002), which supports our observation that
IL-4+ cells could include also other cells than T-cells.
Expression of IL-1α and ICAM-1 in the intestine of T1D patients
Our data on IL-1α in T1D duodenal mucosa imply a general inflammatory process in the
intestines of these patients. IL-1α is a proinflammatory cytokine, suggested to be a key
mediator in inflammatory bowel disease (Youngman et al. 1993). It is produced by
mononuclear but not epithelial cells in inflammatory bowel disease (Youngman et al. 1993).
This is also true for T1D patients as we did not observe any positive staining in the
epithelium. IL-1α increases the expression of ICAM-1 (Dinarello 2002), which we also
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observed in the duodenal mucosa of our T1D patients. The increased ICAM-1 expression
may lead to the infiltration of inflammatory cells into the inflamed tissue. This may be one
explanation for the higher density of CD3+ lamina propria lymphocytes observed in our T1D
patients, as compared with the other patient groups investigated in this thesis. ICAM-1 is also
critical for establishing cell-to-cell contacts between APCs and T-cells, leading to T-cell
activation (Springer 1994). Furthermore, IL-1 participates in the regulation of dendritic cells
and thus also in antigen presentation. Taken together, the increase in ICAM-1 and IL-1α in
the duodenal mucosa of our T1D patients imply that the innate immune system is also
activated in the inflammation process.
Coeliac disease in type 1 diabetes
T1D and CD share the same high-risk HLA-DQ2 and DQ8 haplotypes, but this does not
alone explain the increase of CD in T1D patients. Wheat gluten is associated with the risk of
diabetes in NOD mice and biobreeding rats (Elliott and Martin 1984, Scott 1996).
Furthermore, enhanced response to gluten was demonstrated in PBMCs of newly diagnosed
T1D patients without CD (Klemetti et al. 1998), and by rectal gluten challenge in another
study (Troncone et al. 2003). The enhanced responsiveness to wheat and other dietary
proteins in T1D may be a consequence of broken oral tolerance to antigens in general. This
dysregulation of oral tolerance could play a critical role in the process leading to the
destruction of β-cells and T1D.
In one small series of adolescents with newly diagnosed CD and diabetes
autoantibodies, treatment with a gluten-free diet led to the disappearance of the diabetes-
associated autoantibodies (Not et al. 2001), suggesting that intestinal inflammation may
stimulate beta cell specific immune response.
Our patients with T1D and normal mucosa had suffered from T1D for a longer period
of time than the other two T1D groups, which probably reflects the fact that most cases of CD
in T1D patients are identified within the first years from the diagnosis of T1D (Barera et al.
2002). Although CD is occasionally identified before diagnosis of T1D, in most cases CD
autoantibodies are present at the time of or within two years of T1D diagnosis (Saukkonen et
al. 1996). However, we can not conclude what impact the difference in duration of T1D has
on the cytokine profiles in the intestine. Our results on IL-1α, IL-4, HLA, and ICAM-1
expression indicate that the duration of T1D does not affect the inflammation response. The
findings were not restricted to CD associated HLA-DQ2 risk alleles, suggesting that
activation of the gut immune system is associated with T1D as such. None of the T1D
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patients with potential CD or with normal mucosa has developed clinical CD during the
follow-up, which on the average is 4.8 and 5.5 years, respectively, by the end of April 2004.
This further confirms that our results are not caused by the higher risk of CD in T1D patients.
The densities of IL-2, IFN-γ, and TNF-α positive cells were, nonetheless, associated with the
degree of CD, confirming our results from CD patients in study I. Taken together, our results
suggest that the gut immune system has an important role in T1D.
6. Intestinal cytokine expression after stem cell transplantation (SCT) (III)
Our results on increased apoptosis and proliferation of intestinal crypt epithelial cells
following allogeneic SCT in children is in agreement with other reports on adult patients
(Epstein et al. 1980, Socié et al. 2004). We also demonstrated an increased cell turnover rate
in patients without symptomatic clinical or histological GvHD. The persistence of apoptotic
and proliferative activity still at 3 months may imply an ongoing process, such as infection or
GvHD. However, it is not clear whether the increased cell turnover represents an early stage
of intestinal GvHD in humans similar to animal models. The increased epithelial cell turnover
may also reflect the injury caused by the conditioning regimen during SCT.
Th1/Th2 paradigm in GvHD
Along with the expression of the class II HLA-molecules, cytokines, such as IFN-γ, IL-1α
and TNF-α, are needed for the development of murine GvHD (Hill and Ferrara 2000). In our
patients, the densities of IFN-γ positive cells in the intraepithelial compartment and IL-1α
positive cells in the lamina propria, but not the expression of TNF-α, were increased in the
SCT patients as compared to the normal controls. The densities of IFN-γ and TNF-α positive
cells in the lamina propria of SCT patients were surprisingly low, much lower than in patients
with coeliac disease. On the other hand we found increased densities of IL-4 positive cells,
especially in the biopsies taken at 3 months, which is in conflict with the proposed murine
model of GvHD. Although a Th1 dominance has been implicated in this animal model
(Mowat 1997), the role of Th1/Th2 polarisation is incompletely understood and controversial.
Early polarisation of donor T-cells by administration of IFN-γ, IL-2, or IL-12 to SCT
recipients can prevent acute GvHD. Furthermore, the use of Th1 cytokine-deficient mice as
SCT donors still results in GvHD, and some studies have failed to show a beneficial effect of
Th2 stimulation (reviewed by Reddy 2003). One study suggested that Th1- and Th2-type
cytokines mediate acute GvHD with distinct end-organ targets, and that both responses are
DISCUSSION
___________________________________________________________________________
81
necessary for the development of GvHD (Nikolic et al. 2000). However, to the best of our
knowledge, no data on Th1- and Th2-type responses in human intestinal GvHD is yet
available.
Expression of TNF-α and IL-1α
We demonstrated low densities of TNF-α positive cells in all SCT specimens, also in those
with histological GvHD. This is in conflict with data from animal models, that support the
role of TNF-α in the pathogenesis of intestinal GvHD (Hill and Ferrara 2000). The majority
of data from GvHD derives from murine models that use inbred strains with often limited
genetic disparity compared to clinical settings. The conditions in the animal models are
highly controlled and the environment is pathogen-free. The use of intensive treatment
schedules and immunosuppressive medications in clinical SCT is the biggest difference
between the clinical SCT in patients and the experimental SCT in animal models. This
certainly has its own impact on the development of GvHD, which might explain differences
between our results and those from experimental models.
Nevertheless, our finding is also in conflict with recent human studies. The role of
TNF-α in human GvHD was suggested by the fact that monoclonal anti-TNF-α antibody
provided some benefit to patients with steroid resistant acute and chronic GvHD (Kobbe et al.
2001, Chiang et al. 2002). An increase in TNF-α levels was also detected in the sera of 84
adult SCT patients during the first 30 posttransplantation days, and an increase in TNF-α
levels during the first 11-30 days correlated with the development of major transplantation-
related complications (Schots et al. 2003). The proinflammatory cytokine release was
common to all types of complications and no particular pattern was specific for acute GvHD.
Another study with serum samples from 13 adult patients found increased levels of TNF-α
after transplantation, but no correlation could be observed when TNF-α levels were
compared between patients with and without acute GvHD (Visentainer et al. 2003). However,
the only study so far to detect TNF-α in situ in duodenal biopsies reported increased
expression of TNF-α positive cells in all 95 adult patients with symptoms of acute GvHD
(Socié et al. 2004). Of these, 71 (73%) had histological GvHD, and the duodenal biopsies
were taken within 100 days of SCT from 78 patients. Our paediatric patients were enrolled in
a prospective study and most of the patients did not have symptoms of intestinal GvHD, nor
did they have histologically proven GvHD as the above mentioned studies (Schots et al.
2003, Visentainer et al. 2003, Socié et al. 2004).
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Still, we found increased densities of IL-1α+ cells in the SCT patients. The increase
was higher at 6 weeks compared to 3 months after SCT, suggesting that the initial damage
produced by the conditioning regimen has resolved if no GvHD is developing. Mice
receiving IL-1 after allogeneic SCT have increased mortality, probably due to an accelerated
form of the disease (Reddy 2003). Although administration of IL-1 receptor antagonist (IL-
1Ra) reduces GvHD mortality in animal models, a recent randomised human study failed to
demonstrate any benefit against acute GvHD (Antin et al. 2002). This suggests that IL-1 has a
pleiotropic role in the disease and may be synergistic with TNF-α.
Taken together, our results confirm the fact that only little is known about the normal
course of intestinal immunopathology during the early phases after stem cell transplantation.
It is unlikely that the mechanisms of murine and human GvHD differ completely, but the
impact of the different cytokines and their suggested contribution to the target organ damage
may differ. This might be the reason why clinical trials with specific cytokine antibodies have
not yielded as good results as would have been predicted from the murine models (Bruner
and Farag 2003).
7. Th1 dominance in food allergy (IV)
Our results on increased numbers of IFN-γ expressing cells in the lamina propria of children
with delayed-type food allergy indicates a Th1-dominant response. The increased IFN-γ is in
agreement with an earlier study (Hauer et al. 1997). However, since the start of our study,
there have been a few reports on intestinal cytokines in food allergy, all suggesting other Th-
type responses. Beyer et al. showed that cow's milk protein specific T-cells from the
duodenum of patients with cow's milk gastroenteritis with eosinophilia expressed a Th2
cytokine profile (Beyer et al. 2002). Importantly, in that study only 2 of the 10 allergic
children had elevated specific IgE levels. In another study, reduction of both TGF-β and its
type 1 receptor was detected in the mucosa of 28 infants with food protein-induced
enterocolitis (Chung et al. 2002). Unfortunately, the authors did not examine the expression
of IL-4 or IFN-γ. Recently, Perez-Machado et al. did not find any significant Th1/Th2
skewing by flow cytometry amongst duodenal lymphocytes of 30 children with food allergy
when compared to controls (Perez-Machado et al. 2003). The study included both IgE- (8
patients) and non-IgE mediated reactions (22 patients). In agreement with the previous study,
they found reduced amounts of TGF-β1 lymphocytes both in the intraepithelial compartment
and in the lamina propria. Thus, recent studies suggest that the dominant mucosal
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abnormality in food allergy is not a Th1 or Th2 deviation, but impaired generation of Th3
cells. Regulatory Th3 cells (see Table 1) may be deficient at the site of antigen entry and thus
allow an uncontrolled immune reaction to food antigens to take place.
Morphology of the duodenal bulb
The patchy villous atrophy has been considered one of the characteristics of food protein-
induced enteropathy (Sampson 1999). However, the intestinal damage and the intensity of
gastrointestinal symptoms have been shown to be in close association (McCalla et al. 1980).
When intestinal symptoms are mild, like in the children in the present study, the intestinal
changes have been shown to be minimal. Severity of mucosal deterioration in patients with
food allergy has also been shown to decrease with age. Studies showing patchy lesions or
partial villous atrophy have usually involved younger patients, e.g. Hauer et al. studied
children aged 3-21 months (Hauer et al. 1997), and Chung et al. studied infants aged 24 days-
8 months with cow's milk-sensitive enteropathy (Chung et al. 1999).
Although all but one of the patients with food allergy in this study, and one third of the
patients in a previous study (Kokkonen et al. 2001b), presented with lymphonodular
hyperplasia of the duodenal bulb, it can not be considered specific for this condition. In the
earlier work lymphonodular hyperplasia was also found occasionally among healthy controls
and in one patient with coeliac disease (Kokkonen et al. 2001b). It may be speculated that in
conditions with lymphonodular hyperplasia, the mucosa has failed to downregulate or
suppress the immune responses against luminal antigens, such as food proteins.
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CONCLUSIONS
The present study evaluated the expression of cytokines and immunologic markers in
immunologically mediated inflammations in human small intestine in vivo. Based on the
results presented in this thesis, the main conclusions are:
1) Inflammatory markers can be detected in potential CD long before alterations in the
villous structure take place. The increased numbers of IFN-γ and TNF-α expressing cells in
latent CD patients indicate that a skewing towards a Th1-type response manifests already at
the infiltrative stage of CD.
2) Increased densities of IL-2, IFN-γ, and TNF-α positive cells were associated with CD,
also in T1D patients with CD or potential CD. In this respect T1D patients do not differ from
other CD patients.
3) Signs of immune activation in the small intestine of all patients with T1D supports the
hypothesis that a link exists between the gut immune system and type 1 diabetes. The
increased density of IL-4 positive cells in T1D patients suggests that the immune response
has an unexpected Th2 dominance.
4) The increased cell turnover rate in SCT patients without symptomatic clinical or
histological GvHD, may represent an early stage of intestinal GvHD in humans similar to
animal models. The proposed cytokine expression of animal GvHD was not observed in our
patients undergoing SCT, which may reflect the immunosuppressive medication in SCT
patients.
5) Increased expression of IFN-γ in patients with untreated food allergy suggest an
association of Th1 delayed type immune reaction with food allergy enteropathy.
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